Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols

Paul Z. Chen[1], Niklas Bobrovitz[2-4], Zahra Premji[5], Marion Koopmans[6], David N. Fisman[7,8],

Frank X. Gu[1,9]*

[1]Department of Chemical Engineering & Applied Chemistry, University of Toronto, Toronto,

Canada

[2]Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

[3]Department of Critical Care Medicine, Cumming School of Medicine, University of Calgary,

Calgary, Canada

[4]O'Brien Institute of Public Health, University of Calgary, Calgary, Canada

[5]Libraries & Cultural Resources, University of Calgary, Calgary, Canada

[6]Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands

[7]Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto,

Canada

[8]Division of Infectious Diseases, Temerty Faculty of Medicine, University of Toronto, Toronto,

Canada

[9]Institute of Biomedical Engineering, University of Toronto, Toronto, Canada

*Correspondence: f.gu@utoronto.ca

Abstract

A growing number of studies provide insight into how SARS-CoV-2 spreads[1-7]. Yet, many factors that characterize its transmissibility remain unclear, including mechanistic correlates of overdispersion, viral kinetics, the extent to which respiratory droplets and aerosols carry viable virus and the infectiousness of asymptomatic, presymptomatic and pediatric cases[7]. Here, we developed a comprehensive dataset of respiratory viral loads (rVLs) via systematic review and investigated these factors using meta-analyses and modeling. By comparing cases of COVID-19, SARS and influenza A(H1N1)pdm09, we found that heterogeneity in rVL was associated with overdispersion and facilitated the distinctions in individual variation in infectiousness among these emergent diseases. For COVID-19, case heterogeneity was broad throughout the infectious period, although rVL tended to peak at 1 day from symptom onset (DFSO) and be elevated for 1-5 DFSO. While most cases presented minimal risk, highly infectious ones could spread SARS-CoV-2 by talking, singing or breathing, which shed virions at comparable rates via droplets and aerosols. Coughing shed considerable quantities of virions, predominantly via droplets, and greatly increased the contagiousness of many symptomatic cases relative to asymptomatic ones. Asymptomatic and symptomatic infections showed similar likelihoods of expelling aerosols with SARS-CoV-2, as did adult and pediatric cases. Children tended to be less contagious by droplet spread than adults based on tendencies of symptomatology rather than rVL. Our findings address longstanding questions on SARS-CoV-2 transmissibility and present pertinent considerations for disease control.

Main body

The novel coronavirus SARS-CoV-2 has spread globally, causing the coronavirus disease 2019

(COVID-19) pandemic with more than 38.0 million infections and 1.0 million deaths (as of 13

October 2020)[8]. While the basic reproductive number has been estimated to be 2-3.6[1,2],

transmissibility of SARS-CoV-2 is highly overdispersed, with numerous instances of

superspreading[9-11] and few cases (10-20%) causing many secondary infections (80%)[4-6].

Estimates indicate 40-87% of cases are asymptomatic or paucisymptomatic, which facilitates

transmission[2,3,12]. Infectiousness begins around -3 to -2 DFSO and has been estimated to last 8-

10 DFSO[13-15]. Hence, the temporal infectiousness profile of COVID-19 resembles that of

influenza[16], whereas its overdispersion is similar to that of severe acute respiratory syndrome

(SARS)[17].

For respiratory virus transmission, airway epithelial cells shed virions to the extracellular

fluid before atomization (from breathing, talking, singing, coughing and aerosol-generating

procedures) partitions them into a polydisperse mixture of droplets (>5 μm) and aerosols (≤5

μm) that are expelled to the ambient environment[7]. Based on mass, droplets tend to settle

gravitationally, whereas aerosols remain suspended and travel based on airflow profiles.

Although proximity has been associated with infection risk for COVID-19[18], studies have also

suggested that long-range aerosol spread occurs conditionally[9-11].

Despite these analyses, key factors that characterize the transmissibility of SARS-CoV-2

remain unclear. To investigate many of these factors, we synthesized evidence by systematic

review, compared SARS-CoV-2 rVLs among subgroups, associated overdispersion, analyzed

viral kinetics and modeled the likelihood of shedding viable virus via droplets and aerosols

across respiratory activities, DFSO, case heterogeneity and subgroups. For inference on

transmissibility, we compared these analyses with those of SARS-CoV-1 (the most closely

related human coronavirus) and A(H1N1)pdm09 (the most recent pandemic influenza virus),

which spread by contact, droplets and aerosols[19,20].

Systematic review

To develop the comprehensive dataset, we conducted a systematic review on quantitative VL

measurements for respiratory specimens taken during the infectious periods of SARS-CoV-2 (-3

to 10 DFSO)[13-15], SARS-CoV-1 (0-20 DFSO)[21] and A(H1N1)pdm09 (-2 to 9 DFSO)[16]

(Methods). The systematic search (Supplementary Tables 1-5) identified 4,274 results. After

screening and full-text review, 63 studies met the inclusion criteria and were used for analysis

(Fig. 1) (n=9,692 total specimens), which included adult (n=5,124) and pediatric (n=1,593) cases

and measurements for asymptomatic (n=2,378), presymptomatic (n=28) and symptomatic

(n=7,231) infections. According to a hybrid Joanna Briggs Institute critical appraisal checklist,

risk of bias was low to moderate for included studies (Extended Data Table 1).

Meta-analysis and subgroup analyses of rVL

For each study in the systematic dataset, we used specimen concentrations to estimate rVLs

(Methods). We then performed a random-effects meta-analysis (Extended Data Fig. 1), which

showed that, during the infectious periods, the expected rVL of SARS-CoV-2 was comparable to

that of SARS-CoV-1 (p=0.148, two-sided Welch's t-test) but lesser than that of A(H1N1)pdm09

(p<0.0001). We also performed random-effects subgroup analyses for COVID-19 (Fig. 2), which

showed that expected SARS-CoV-2 rVLs were consistent between pediatric and adult cases

(p=0.861) and between symptomatic/presymptomatic and asymptomatic infections (p=0.951).

Association of heterogeneity in rVL with overdispersion

Since few cases drive the transmission of SARS-CoV-2 (dispersion parameter k, 0.10-0.58)[4-6]

and SARS-CoV-1 (k, 0.16-0.17)[17] whereas A(H1N1)pdm09 (k, 7.4-14.4)[22,23] spreads more

homogeneously, we sought to find a mechanistic association for overdispersion. As an empirical

estimate, k depends on myriad extrinsic (behavioral, environmental and invention) and host (host

defenses) factors. However, since dispersion is similar across distinct outbreaks of a virus[17], we

hypothesized that an intrinsic virological factor mediates k for these emergent respiratory

infections.

　　We assessed heterogeneity in rVL. For all three viruses, rVLs best conformed to Weibull

distributions (Extended Data Fig. 2), and we fitted the entirety of individual sample data for each

virus in the systematic dataset (Fig. 3a, Extended Data Fig. 2n). While COVID-19 and SARS

cases tended to shed lesser virus than those with A(H1N1)pdm09 (Extended Data Fig. 1), broad

heterogeneity in rVL inverted this relationship for highly infectious individuals (Extended Data

Fig. 3a-c). At the 90th case percentile (cp), the estimated rVL was 8.91 (8.82-9.00, 95%

confidence interval [CI]) $\log_{10}$ copies/ml for SARS-CoV-2, whereas it was 8.62 (8.47-8.76) $\log_{10}$

copies/ml for A(H1N1)pdm09. Moreover, heterogeneity in rVL was similar among adult,

pediatric, symptomatic/presymptomatic and asymptomatic COVID-19 cases (Extended Data Fig.

3d-g), with standard deviations (SDs) of 2.01-2.06 $\log_{10}$ copies/ml (Extended Data Table 2).

　　To investigate the relationship between k and heterogeneity in rVL, we performed a meta-

regression using each included study (Fig. 3b). The analysis showed a negative association

(p=0.031, meta-regression slope t-test), indicating that heterogeneity in rVL intrinsically

facilitated the distinctions in overdispersion among the emergent infections.

Kinetics of SARS-CoV-2 rVL

To investigate dynamics, we delineated SARS-CoV-2 rVLs by DFSO and fitted the mean

estimates to a mechanistic epithelial cell-limited model for viral kinetics (Fig. 3c, Methods). The

outputs indicated that, on average, each productively infected cell in the airway epithelium shed

SARS-CoV-2 at 1.11 (0.51-1.71, 95% CI) copies/ml day^{-1} and infected up to 10.6 susceptible

cells (Extended Data Table 3). The turnover rate for infected epithelial cells was 0.55 (0.23-0.87)

days^{-1}, while the half-life of SARS-CoV-2 in the respiratory tract was 4.35 (2.23-97.8) hours. By

extrapolating the model to an initial rVL of 0-1 log$_{10}$ copies/ml, the estimated incubation period

was 5.38-4.52 days, which agrees with epidemiological findings[1]. Conversely, the expected

duration of shedding was 26.8 DFSO. Thus, SARS-CoV-2 replicated exponentially in the

respiratory tract based on a mean rate constant of 4.02×10^{-7} (3.01×10^{-7}-5.03×10^{-7}) (copies/ml)$^{-1}$

day^{-1} after infection. Around 1 DFSO, rVL peaked, as the number of infected epithelial cells

reached equilibrium, and then diminished exponentially.

    As SARS-CoV-2 rVLs showed widespread heterogeneity across the infectious period, we

fitted distributions for each DFSO (Fig. 3d), which showed that high rVLs also increased from

the presymptomatic period before decreasing towards the end of the first week of illness. At the

90th cp, SARS-CoV-2 rVL peaked at 1 DFSO at 9.83 (9.12-10.61) log$_{10}$ copies/ml, an order of

magnitude greater than the overall 90th-cp estimate (Extended Data Table 2). The estimate

remained ≥9.33 log$_{10}$ copies/ml between 1-5 DFSO. At -1 DFSO, the 90th-cp rVL was 8.30

(6.88-10.02) log$_{10}$ copies/ml, while it was 7.92 (7.34-8.55) log$_{10}$ copies/ml at 10 DFSO

(Extended Data Fig. 3h-s).

Likelihood of droplets and aerosols containing virions

Since rVL is an intensive quantity, the volume fraction of virions is low and viral partitioning

coincides with atomization, we used Poisson statistics to model likelihood profiles. To calculate

an unbiased estimator of partitioning (the expected number of viable copies per particle), our

method multiplied rVL estimates with the volumes of atomized particles and an assumed

viability proportion of 0.1% after dehydration (Methods).

When expelled by the mean COVID-19 case across the infectious period, respiratory

particles showed minimal likelihoods of carrying viable SARS-CoV-2 (Fig. 4a,b). Aerosols

(dehydrated aerodynamic diameter [d_a]≤5 µm) were <0.001% likely to contain a virion. Droplets

also had low likelihoods: at d_a=40 µm, they were ≤0.4% likely to contain a virion.

COVID-19 cases with high rVLs, however, expelled particles with considerably greater

likelihoods of carrying viable copies (Fig. 4a,b). For the 98th cp at 1 DFSO, 18.2% (8.8-27.6%)

of aerosols (d_a=5 µm) contained at least one SARS-CoV-2 virion. For d_a>14.4 µm, droplets were

>99% likely to contain virions, with large ones carrying tens to hundreds.

Shedding SARS-CoV-2 via respiratory activities

Using the partitioning estimates in conjunction with published profiles of the particles expelled

by respiratory activities (Extended Data Fig. 4), we modeled the rates at which talking, singing,

breathing and coughing shed viable SARS-CoV-2 across d_a (Fig. 4c-f). Among the non-

presenting activities, singing emitted virions most rapidly followed by talking and then

breathing, although talking loudly was similar to singing (Extended Data Fig. 4c,d). These

activities produced more aerosols than droplets, but particle size correlated with the likelihood of

containing virions. Thus, talking, singing and breathing shed SARS-CoV-2 at similar rates via

aerosols and droplets: aerosols mediated 25.2-43.4% of the virions expelled by the non-

presenting activities (Fig. 4g). In comparison, coughing shed far greater quantities of virions

(Fig. 4f), of which >99.9% were carried by droplets.

We further examined the influences of case heterogeneity and disease course on expelling

SARS-CoV-2 (Fig. 4h, Extended Data Fig. 5). The estimated total shedding rates (over all

particle sizes) for a respiratory activity spanned ≥8.55 orders of magnitude on each DFSO;

cumulatively from -1 to 10 DFSO, they spanned 11.2 orders of magnitude. Hence, most cases

expelled a negligible number of SARS-CoV-2 virions by talking, singing or breathing. Shedding

occurred most rapidly at 1 DFSO: for the 98th cp, singing discharged 31.5 (3.26-379, 95% CI)

virions/min to the ambient environment, while talking emitted 4.67 (0.48-56.1) virions/min and

breathing exhaled 1.27 (0.13-15.2) virions/min; these estimates were two orders of magnitude

greater than those for the 86th cp. For the 98th cp at -1 DFSO, singing shed 1.31 (0.01-406)

virions/min and breathing exhaled 5.24×10^{-2} (5.28×10^{-4}-16.3) virions/min. The estimates at 7-10

DFSO were comparable to these presymptomatic ones (Fig. 4h, Extended Data Fig. 5).

At 1 DFSO, coughing expelled 2.13×10^{6} (2.20×10^{5}-2.56×10^{7}) virions/cough for the 98th cp,

90.4 (24.6-372) virions/cough for the 50th cp and 2.66 (0.65-13.1) virions/cough for the 25th cp

(Extended Data Fig. 5c). At -1 and 10 DFSO, these estimates were reduced by ~2 orders of

magnitude. Thus, most symptomatic cases shed considerable quantities of SARS-CoV-2 by

coughing; a single cough accounted for the virions emitted by weeks of singing for a case.

As indicated by similar mean rVLs (Fig. 2) and heterogeneities in rVL (Extended Data

Table 2), asymptomatic, symptomatic/presymptomatic, adult and pediatric COVID-19 cases

showed similar profiles for total shedding rates (Extended Fig. 6a-d). The estimates showed that

the top 6.1%, 2.4% and 1.1% of pediatric cases shed ≥1 virion/min by singing, talking and

breathing, respectively, while 62.5% expelled ≥10 virions/cough. In general, highly infectious

COVID-19 cases expelled virions more rapidly than did ones with A(H1N1)pdm09 (Extended

Data Fig. 6f).

Discussion

This study provided comprehensive, systematic analyses of several factors characterizing the

transmissibility of SARS-CoV-2. First, we evaluated the influence of heterogeneity in rVL. Our

findings show that broad heterogeneity in rVL facilitates greater variation in individual

infectiousness in the COVID-19 pandemic than was found in the 2009 H1N1 pandemic. For each

respiratory activity, SARS-CoV-2 shedding rates span >11 orders of magnitude throughout the

infectious period. While most COVID-19 cases present minimal transmission risk by talking,

singing or breathing, highly infectious ones, including asymptomatic and presymptomatic

infections, can spread SARS-CoV-2 through these activities. Our model estimates, when

corrected to copies rather than virions, align with recent clinical findings for exhalation rates of

SARS-CoV-2[24]. Moreover, the findings suggest that heterogeneity in rVL may be a virological

factor generally associated with overdispersion for respiratory infections. In this case, rVL

distribution may serve as an early correlate for transmission patterns, including superspreading,

during outbreaks of novel respiratory viruses, providing insight for disease control before large-

scale epidemiological analyses empirically characterize *k*.

Second, we analyzed SARS-CoV-2 kinetics during respiratory infection. While

heterogeneity remains broad throughout the infectious period, the systematic dataset indicates

that rVL tends to peak at 1 DFSO and be elevated for 1-5 DFSO, coinciding with the period of

highest attack rates observed among close contacts[25]. These results indicate that transmission risk

tends to be greatest soon after illness rather than in the presymptomatic period, which concurs

with large tracing studies (6.4-12.6% of secondary infections from presymptomatic

transmission)[26,27] rather than early temporal models (~44%)[14]. Furthermore, our kinetic analysis

suggests that, on average, SARS-CoV-2 reaches diagnostic concentrations 1.60-3.22 days after

respiratory infection (-3.78 to -2.16 DFSO), assuming assay detection limits of 1-3 $\log_{10}$

copies/ml, respectively, for nasopharyngeal swabs immersed in 1 ml of transport media.

Third, we modeled the likelihood of shedding SARS-CoV-2 via aerosols. Talking, singing

and breathing shed SARS-CoV-2 at comparable rates through droplets and aerosols (up to tens to

hundreds of virions/min). As airborne spread is recognized as a key mode of transmission for

A(H1N1)pdm09[20], our model estimates and comparative analyses support, particularly for highly

infectious cases, airborne spread as a transmission mode for SARS-CoV-2. While our models

delineated aerosols from droplets at the classical threshold (d_a=5 μm), recent reports show that,

based on emission vectors and environmental conditions, respiratory particles larger than 5 μm

can also travel >2 m in air[28,29], further supporting the plausibility of the airborne transmission of

SARS-CoV-2. However, with short durations of stay in well-ventilated areas, the concentration,

and exposure risk, of aerosols remains correlated with proximity to infectious cases[18,28].

Fourth, we assessed the relative infectiousness of COVID-19 subgroups. Since rVL

distributions are similar among subgroups and the predominant source of aerosols is the non-

presenting respiratory activities (talking, singing and breathing), symptomatic and asymptomatic

infections present similar risks for aerosol spread, as do adult and pediatric cases. However, most

cases shed considerable numbers of virions via large droplets by coughing, a common symptom

of COVID-19[30]. Thus, symptomatic infections tend to be significantly more contagious than

asymptomatic ones, providing a reason as to why asymptomatic cases transmit SARS-CoV-2 at

lower relative rates[3], especially in close contact[31], despite similar rVLs and increased contact

patterns. Accordingly, children (48-54% of symptomatic cases present with cough)[32,33] tend to be

less contagious by droplet spread than adults (68-80%)[30,33] based on tendencies of

symptomatology rather than rVL.

Our study has limitations. The systematic search found a limited number of studies reporting

quantitative specimen measurements from the presymptomatic period, meaning these estimates

may be sensitive to sampling bias. Although additional studies have reported semiquantitative

metrics (cycle thresholds), these data were excluded because they cannot be compared on an

absolute scale due to batch effects[34], limiting use in compound analyses. Furthermore, our

analyses considered population-level estimates of the infectious periods and viability

proportions, which omit individual variation in the dynamics of virus viability. Some patients

shed SARS-CoV-2 with diminishing viability soon after symptom onset[13], while others produce

replication-competent virus for weeks[35]. It remains unelucidated how case characteristics and

environmental factors affect the viability dynamics of SARS-CoV-2.

Taken together, our findings provide a potential path forward for disease control. They

highlight the disproportionate role of high-risk cases, settings and circumstances in propelling

the COVID-19 pandemic. Since highly infectious cases, regardless of age or symptomatology,

can rapidly shed SARS-CoV-2 via both droplets and aerosols, airborne spread should also be

recognized as a transmission risk, including for superspreading. Strategies to abate infection

should limit crowd numbers and duration of stay while reinforcing distancing and then

widespread mask usage; well-ventilated settings can be recognized as lower risk venues.

Coughing sheds considerable quantities of virions for most infections, while rVL tends to peak at

1 DFSO and can be high throughout the infectious period. Thus, immediate, sustained self-

isolation upon symptom presentation is crucial to curb transmission from symptomatic cases.

While diagnosing COVID-19, qRT-PCR can also help to triage contact tracing, prioritizing

patients with higher specimen measurements: for nasopharyngeal swabs immersed in 1 ml of

transport media, ≥ 7.14 (7.07-7.22, 95% CI) $\log_{10}$ copies/ml corresponds to $\geq 80^{th}$ cp. Doing so

may identify asymptomatic and presymptomatic cases more efficiently, a key step towards

mitigation as the pandemic continues.

References

1 Li, Q. *et al.* Early transmission dynamics in Wuhan, China, of novel coronavirus-infected

pneumonia. *N. Engl. J. Med.* **382**, 1199-1207, doi:10.1056/NEJMoa2001316 (2020).

2 Hao, X. *et al.* Reconstruction of the full transmission dynamics of COVID-19 in Wuhan.

Nature **584**, 420-424, doi:10.1038/s41586-020-2554-8 (2020).

3 Li, R. *et al.* Substantial undocumented infection facilitates the rapid dissemination of novel

coronavirus (SARS-CoV-2). *Science* **368**, 489-493, doi:10.1126/science.abb3221 (2020).

4 Endo, A., Abbott, S., Kucharski, A. J. & Funk, S. Estimating the overdispersion in

COVID-19 transmission using outbreak sizes outside China. *Wellcome Open Research* **5**,

doi:10.12688/wellcomeopenres.15842.1 (2020).

5 Laxminarayan, R. *et al.* Epidemiology and transmission dynamics of COVID-19 in two

Indian states. *Science*, eabd7672, doi:10.1126/science.abd7672 (2020).

6 Bi, Q. *et al.* Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their

close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect. Dis.* **20**,

911-919, doi:10.1016/s1473-3099(20)30287-5 (2020).

7 Organization, W. H. Transmission of SARS-CoV-2: implications for infection prevention

precautions (scientific brief). July 9, 2020.

8 Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in

real time. *Lancet Infect. Dis.* **20**, 533-534, doi:10.1016/S1473-3099(20)30120-1 (2020).

9 Shen, Y. *et al.* Community outbreak investigation of SARS-CoV-2 transmission among

bus riders in Eastern China. *JAMA Intern. Med.*, doi:10.1001/jamainternmed.2020.5225

(2020).

10   Lu, J. *et al.* COVID-19 outbreak associated with air conditioning in restaurant, Guangzhou,

China, 2020. *Emerg. Infect. Dis.* **26**, 1628-1631, doi:10.3201/eid2607.200764 (2020).

11   Hamner, L. *et al.* High SARS-CoV-2 attack rate following exposure at a choir practice -

Skagit County, Washington, March 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 606-610,

doi:10.15585/mmwr.mm6919e6 (2020).

12   Oran, D. P. & Topol, E. J. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative

review. *Ann. Intern. Med.* **173**, 362-367, doi:10.7326/M20-3012 (2020).

13   Wolfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature*

581, 465-469, doi:10.1038/s41586-020-2196-x (2020).

14   He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat.*

Med. **26**, 672-675, doi:10.1038/s41591-020-0869-5 (2020).

15   Arons, M. M. *et al.* Presymptomatic SARS-CoV-2 infections and transmission in a skilled

nursing facility. *N. Engl. J. Med.* **382**, 2081-2090, doi:10.1056/NEJMoa2008457 (2020).

16   Ip, D. K. *et al.* Viral shedding and transmission potential of asymptomatic and

paucisymptomatic influenza virus infections in the community. *Clin. Infect. Dis.* **64**, 736-

742, doi:10.1093/cid/ciw841 (2017).

17   Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E. & Getz, W. M. Superspreading and the

effect of individual variation on disease emergence. *Nature* **438**, 355-359,

doi:10.1038/nature04153 (2005).

18   Chu, D. K. *et al.* Physical distancing, face masks, and eye protection to prevent person-to-

person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-

analysis. *Lancet* **395**, 1973-1987, doi:10.1016/S0140-6736(20)31142-9 (2020).

19   Yu, I. T. *et al.* Evidence of airborne transmission of the severe acute respiratory syndrome

virus. *N. Engl. J. Med.* **350**, 1731-1739, doi:10.1056/NEJMoa032867 (2004).

20   Cowling, B. J. *et al.* Aerosol transmission is an important mode of influenza A virus

spread. *Nat. Commun.* **4**, 1935, doi:10.1038/ncomms2922 (2013).

21   Pitzer, V. E., Leung, G. M. & Lipsitch, M. Estimating variability in the transmission of

severe acute respiratory syndrome to household contacts in Hong Kong, China. *Am. J.*

Epidemiol. **166**, 355-363, doi:10.1093/aje/kwm082 (2007).

22   Roberts, M. G. & Nishiura, H. Early estimation of the reproduction number in the presence

of imported cases: pandemic influenza H1N1-2009 in New Zealand. *PLoS One* **6**, e17835,

doi:10.1371/journal.pone.0017835 (2011).

23   Brugger, J. & Althaus, C. L. Transmission of and susceptibility to seasonal influenza in

Switzerland from 2003 to 2015. *Epidemics* **30**, 100373, doi:10.1016/j.epidem.2019.100373

(2020).

24   Ma, J. *et al.* COVID-19 patients in earlier stages exhaled millions of SARS-CoV-2 per

hour. *Clin. Infect. Dis.*, doi:10.1093/cid/ciaa1283 (2020).

25   Cheng, H. Y. *et al.* Contact tracing assessment of COVID-19 transmission dynamics in

Taiwan and risk at different exposure periods before and after symptom onset. *JAMA*

Intern. Med., doi:10.1001/jamainternmed.2020.2020 (2020).

26   Wei, W. E. *et al.* Presymptomatic transmission of SARS-CoV-2 — Singapore, January 23-

March 16, 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 411-415,

doi:10.15585/mmwr.mm6914e1 (2020).

27   Du, Z. *et al.* Serial interval of COVID-19 among publicly reported confirmed cases.

Emerg. Infect. Dis. **26**, 1341-1343, doi:10.3201/eid2606.200357 (2020).

28 Abkarian, M., Mendez, S., Xue, N., Yang, F. & Stone, H. A. Speech can produce jet-like

transport relevant to asymptomatic spreading of virus. *Proc. Natl. Acad. Sci. U. S. A.*,

doi:10.1073/pnas.2012156117 (2020).

29 Bourouiba, L. Turbulent gas clouds and respiratory pathogen emissions: potential

implications for reducing transmission of COVID-19. *JAMA* **323**, 1837-1838,

doi:10.1001/jama.2020.4756 (2020).

30 Guan, W. J. *et al.* Clinical characteristics of coronavirus disease 2019 in China. *N. Engl. J.*

Med. **382**, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).

31 Luo, L. *et al.* Contact settings and risk for transmission in 3410 close contacts of patients

with COVID-19 in Guangzhou, China: a prospective cohort study. *Ann. Intern. Med.*,

doi:10.7326/M20-2671 (2020).

32 Lu, X. *et al.* SARS-CoV-2 infection in children. *N. Engl. J. Med.* **382**, 1663-1665,

doi:10.1056/NEJMc2005073 (2020).

33 CDC COVID-19 Response Team. Coronavirus disease 2019 in children - United States,

February 12-April 2, 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 422-426,

doi:10.15585/mmwr.mm6914e4 (2020).

34 Han, M. S., Byun, J. H., Cho, Y. & Rim, J. H. RT-PCR for SARS-CoV-2: quantitative

versus qualitative. *Lancet Infect. Dis.*, doi:10.1016/S1473-3099(20)30424-2 (2020).

35 van Kampen, J. J. A. *et al.* Shedding of infectious virus in hospitalized patients with

coronavirus disease-2019 (COVID-19): duration and key determinants. Preprint at

medRxiv doi:10.1101/2020.06.08.20125310 (2020).

Fig. 1. Development of the systematic dataset.

Subgroup, study ref.	Cases		Specimens			Respiratory viral load, $\log_{10}$ copies/ml (95% CI)	p-value for difference
	No.	Type	No.	DFSO	Type		
Adult							
42	4	H, A, S	9	4 to 10	NPS, OPS	4.12 (3.18-5.05)	
43	100	H, C, A, S, Ps, As	106	-2 to 10	NPS, OPS	4.65 (4.35-4.95)	
44	6	H, A, S	6	3 to 8	OPS	5.13 (4.83-5.42)	
45	23	H, A, S	51	0 to 10	ETA, POS	5.29 (4.65-5.93)	
46	14	H, A, S, As	55	0 to 10	NPS, OPS	5.30 (4.87-5.74)	
47	-	H, N, A, S	31	2 to 10	NPS, OPS, Spu	5.41 (4.81-6.01)	
48	-	H, A, S	19	1 to 10	POS, Spu	5.62 (5.22-6.03)	
49	2,182	C, A, As	2,182	0	NPS	6.01 (5.93-6.09)	
50	171	N, A, S	171	0 to 10	NPS	6.07 (5.79-6.34)	
51	103	H, N, A, S	103	0 to 8	NPS, OPS	6.10 (5.98-6.23)	
13	9	H, A, S, As	133	2 to 10	NPS, OPS, Spu	6.21 (5.90-6.52)	
52	41	H, A, S	310	2 to 10	NPS, OPS, POS	6.28 (6.05-6.50)	
53	5	H, A, S	5	7 to 9	NPS	6.48 (5.26-7.70)	
54	-	H, A, S, As	38	0 to 9	NPA, NPS, OPS, Spu	6.52 (5.77-7.27)	
55	347	H, A, S	347	0 to 5	NPS	6.97 (6.77-7.18)	
56	24	H, A, S	33	0 to 10	NPS	7.51 (6.97-8.05)	
57	205	H, N, A, S	205	0 to 10	NPS	7.55 (7.30-7.81)	
35	-	H, A, S	154	0 to 10	NPS, Spu	7.83 (7.58-8.08)	
58	148	N, A, S	296	1 to 8	NPS	8.04 (7.81-8.28)	
59	5	H, A, S	63	0 to 10	NPS, OPS	8.34 (7.95-8.73)	
Overall ($Q_{19} = 10.1$, $p = 0.95$, $I^2 = 0.0\%$)						6.10 (5.96-6.24)	-
Pediatric							
43	2	H, C, P, S	3	8 to 9	NPS, OPS	3.77 (1.74-5.81)	
60	7	H, P, S, Ps, As	14	-1 to 10	NPS	5.69 (5.26-6.12)	
61	54	C, P, S, Ps, As	54	-3 to 10	NPS	5.82 (5.36-6.29)	
55	58	H, P, S	58	0 to 5	NPS	6.97 (6.45-7.49)	
62	23	H, P, S	23	0 to 4	NPS	7.20 (6.23-8.16)	
63	12	H, P, S, As	27	0 to 10	NPS	8.07 (7.47-8.67)	
Overall ($Q_5 = 3.76$, $p = 0.59$, $I^2 = 0.0\%$)						6.15 (5.60-6.70)	0.861
Symptomatic/presymptomatic							
42	4	H, A, S	9	4 to 10	NPS, OPS	4.12 (3.18-5.05)	
43	53	H, C, A, P, S, Ps	60	-2 to 10	NPS, OPS	4.43 (4.03-4.84)	
44	6	H, A, S	6	3 to 8	OPS	5.13 (4.83-5.42)	
46	13	H, A, S	51	0 to 10	NPS, OPS	5.25 (4.79-5.71)	
45	23	H, A, S	51	0 to 10	ETA, POS	5.29 (4.65-5.93)	
47	-	H, N, A, S	31	2 to 10	NPS, OPS, Spu	5.41 (4.81-6.01)	
48	-	H, A, S	19	1 to 10	POS, Spu	5.62 (5.22-6.03)	
60	6	H, P, S, Ps	13	-1 to 10	NPS	5.77 (5.10-6.53)	
61	81	C, A, P, S, Ps	81	-3 to 10	NPS	5.78 (5.41-6.15)	
13	8	H, A, S	129	2 to 10	NPS, OPS, Spu	5.88 (5.60-6.17)	
64	75	H, S, Ps	104	-1 to 8	OPS, Spu	5.98 (5.31-6.66)	
50	171	N, A, S	171	0 to 10	NPS	6.07 (5.79-6.34)	
51	103	H, N, A, S	103	0 to 8	NPS, OPS	6.10 (5.98-6.23)	
52	41	H, A, S	310	2 to 10	NPS, OPS, POS	6.28 (6.05-6.50)	
53	5	H, A, S	5	7 to 9	NPS	6.48 (5.26-7.70)	
55	405	H, A, P, S	405	0 to 5	NPS	6.95 (6.78-7.17)	
62	23	H, P, S	23	0 to 4	NPS	7.20 (6.23-8.16)	
56	24	H, A, S	33	0 to 10	NPS	7.51 (6.97-8.05)	
57	205	H, N, A, S	205	0 to 10	NPS	7.55 (7.30-7.81)	
35	-	H, A, S	154	0 to 10	NPS, Spu	7.83 (7.58-8.08)	
65	2	H, A, P, S	8	4 to 10	NPS, OPS	7.91 (6.69-9.12)	
58	148	N, A, S	296	1 to 8	NPS	8.04 (7.81-8.28)	
63	9	H, P, S	20	0 to 10	NPS	8.10 (7.37-8.33)	
59	5	H, A, S	63	0 to 10	NPS, OPS	8.34 (7.95-8.73)	
Overall ($Q_{23} = 13.2$, $p = 0.95$, $I^2 = 0.0\%$)						6.18 (6.06-6.29)	-
Asymptomatic							
43	49	H, C, A, As	49	0	NPS, OPS	4.89 (4.46-5.33)	
61	52	C, A, P, As	52	0	NPS	5.31 (4.85-5.77)	
49	2,200	C, A, P, As	2,200	0	NPS	6.01 (5.93-6.09)	
63	3	H, P, As	7	0 to 8	NPS	8.01 (6.91-9.11)	
Overall ($Q_3 = 2.49$, $p = 0.48$, $I^2 = 0.0\%$)						6.15 (5.34-6.96)	0.951

Fig. 2. Subgroup analyses of SARS-CoV-2 respiratory viral load during the infectious

period. Random-effects meta-analyses comparing the expected rVLs of adult (>18 years old)

COVID-19 cases with pediatric (≤18 years old) ones (top) and symptomatic/presymptomatic

infections with asymptomatic ones (bottom) during the infectious period. Quantitative specimen

measurements were used to estimate rVLs, which refer to virus concentrations in the respiratory

tract. Case types: hospitalized (H), not admitted (N), community (C), adult (A), pediatric (P),

symptomatic (S), presymptomatic (Ps) and asymptomatic (As). Specimen types: endotracheal

aspirate (ETA), nasopharyngeal aspirate (NPA), nasopharyngeal swab (NPS), oropharyngeal

swab (OPS), posterior oropharyngeal saliva (POS) and sputum (Spu). Studies after ref. 35 are

listed in Methods. Dashes denote case numbers that were not obtained. Box sizes are

proportional to weighting in the overall estimates. Two-sided Welch's *t*-tests, non-significance

($p>0.05$).

Fig. 3. Heterogeneity and kinetics of SARS-CoV-2 respiratory viral load. a, Estimated

distribution of rVL for SARS-CoV-2 (*n*=3,778 samples from *n*=24 studies) and A(H1N1)pdm09

(*n*=512 samples from *n*=10 studies) throughout the infectious periods. **b,** Meta-regression of

dispersion parameter (*k*) with the standard deviation (SD) of rVLs from included studies (*r*=-

0.27). Estimates of *k* were pooled from the literature. Red, yellow and blue circles denote

COVID-19 (*n*=27), SARS (*n*=9) and A(H1N1)pdm09 (*n*=27) studies, respectively. Circle sizes

are proportional to weighting in the meta-regression. The *p*-value was obtained using the meta-

regression slope *t*-test. **c,** SARS-CoV-2 rVLs fitted to a mechanistic model of viral kinetics

(black curve, r^2=0.88). Filled circles and bars depict mean estimates and 95% CIs. Open circles

show the entirety of individual sample data over DFSO (left to right, *n*=3, 15, 48, 59, 69, 71, 81,

87, 102, 125, 119, 117 and 110 samples from *n*=19 studies). **d,** Estimated distributions of SARS-

CoV-2 rVL over DFSO. Earlier DFSO were excluded based on limited data. Weibull

distributions were fitted on the entirety of individual sample data for the virus (**a**) or DFSO (**d**) in

the systematic dataset. Arrows denote 90th case percentiles for SARS-CoV-2 rVL.

Fig. 4. Heterogeneity in shedding SARS-CoV-2 via droplets and aerosols. a,b, Likelihood of

respiratory particles containing viable SARS-CoV-2 when expelled by the mean (top) or 98th

case percentile (cp) (bottom) COVID-19 cases at -1 (**a**) or 1 (**b**) DFSO. The models considered

virus viability within dehydrated particles. Diameters during atomization were included to show

their size relationship with dehydrated aerodynamic diameter (d_a), but not likelihood of

containing virions during atomization. For higher no. of virions, some likelihood curves were

omitted to aid visualization. When the likelihood for 0 virions approaches 0%, particles are

expected to contain at least one viable copy. **c-f**, Rate that the mean and 98th-cp COVID-19 cases

at 1 DFSO shed viable SARS-CoV-2 by talking (**c**), singing (**d**), breathing (**e**) or coughing (**f**)

over d_a. **g**, Relative contribution of aerosols ($d_a \leq 5$ μm, red bar) and droplets ($d_a > 5$ μm, blue bar)

to shedding virions for the respiratory activities. **h**, Case heterogeneity in the total shedding rate

(over all particle sizes) of virions via singing across the infectious period. Earlier

presymptomatic days were excluded based on limited data. Data range between the 1st and 99th

cps. Lines and bands represent estimates and 95% CIs, respectively, for likelihoods or Poisson

means.

Methods

Search strategy, selection criteria and data collection

We undertook a systematic review and prospectively submitted the systematic review protocol

for registration on PROSPERO (registration number, CRD42020204637). Other than the title of

this study, we have followed PRISMA reporting guidelines[36]. The systematic review was

conducted according to Cochrane methods guidance[37].

The search included papers that (i) reported positive, quantitative measurements (copies/ml

or an equivalent metric) of SARS-CoV-2, SARS-CoV-1 or A(H1N1)pdm09 in human

respiratory specimens (ETA, NPA, NPS, OPS, POS and Spu) from COVID-19, SARS or

A(H1N1)pdm09 cases; (ii) reported data that could be extracted from the infectious periods of

SARS-CoV-2 (defined as -3 to +10 DFSO for symptomatic cases and 0 to +10 days from the day

of laboratory diagnosis for asymptomatic cases), SARS-CoV-1 (defined as 0 to +20 DFSO or the

equivalent asymptomatic period) or A(H1N1)pdm09 (defined as -2 to +9 DFSO for symptomatic

cases and 0 days to +9 days from the day of laboratory diagnosis for asymptomatic cases); and

(iii) reported data for two or more cases with laboratory-confirmed COVID-19, SARS or

A(H1N1)pdm09. Quantitative specimen measurements were considered after RNA extraction for

diagnostic sequences of SARS-CoV-2 (*Ofr1b*, *N*, *RdRp* and *E* genes), SARS-CoV-1 (*Ofr1b*, *N*

and *RdRp* genes) and A(H1N1)pdm09 (*HA* and *M* genes).

Studies were excluded, in the following order, if they (i) studied an ineligible disease; (ii)

had an ineligible study design, including those that were reviews of evidence (e.g., scoping,

systematic, narrative), did not include primary clinical human data, reported data for less than

two cases due to an increased risk of selection bias, were incomplete (e.g., ongoing clinical

trials), did not report an RNA extraction step before measurement or were studies measuring

environmental samples; (iii) reported an ineligible metric for specimen concentration (e.g.,

qualitative RT-PCR or cycle threshold [Ct] values without calibration included in the study); (iv)

reported quantitative measurements from an ineligible specimen type (e.g., blood specimens,

pooled specimens or self-collected POS or Spu patient specimens in the absence of a healthcare

professional); (v) reported an ineligible sampling period (consisted entirely of data that could not

be extracted from within the infectious period); or (vi) were duplicates of an included study (e.g.,

preprinted version of published paper or duplicates not identified by Covidence). We included

data from control groups receiving standard of care in interventional studies but excluded data

from the intervention group. Patients in the intervention group are, by definition, systematically

different from general case populations because they receive therapies not being widely used for

treatment, which may influence virus concentrations. Interventional studies examining the

comparative effectiveness of two or more treatments were excluded for the same reason. Studies

exclusively reporting semiquantitative measurements (e.g., Ct values) of specimen concentration

were excluded, as these measurements are sensitive to batch inconsistencies and, without proper

calibration, cannot be compared on an absolute scale across studies[34].

We searched, without the use of filters or language restrictions, the following sources:

MEDLINE (via Ovid, 1946 to 7 August 2020), EMBASE (via Ovid, 1974 to 7 August 2020,

Cochrane Central Register of Controlled Trials (via Ovid, 1991 to 7 August 2020), Web of

Science Core Collection (including: Science Citation Index Expanded, 1900 to 7 August 2020;

Social Sciences Citation Index, 1900 to 7 August 2020; Arts & Humanities Citation Index, 1975

to 7 August 2020; Conference Proceedings Citation Index - Science, 1990 to 7 August 2020;

Conference Proceedings Citation Index - Social Sciences & Humanities, 1990 to 7 August 2020;

and Emerging Sources Citation Index, 2015 to 7 August 2020), as well as MedRxiv and BioRxiv

(both searched through Google Scholar via the Publish or Perish program, to 7 August 2020).

We also gathered studies by searching through the reference lists of review articles identified by

the database search, by searching through the reference lists of included articles, through expert

recommendation (by Epic J. Topol, Akiko Iwasaki and A. Marm Kilpatrick on Twitter) and by

hand-searching through journals (*Nature*, *Nat. Med.*, *Science*, *NEJM*, *Lancet*, *Lancet Infect. Dis.*,

JAMA, *JAMA Intern. Med.* and *BMJ*). A comprehensive search was developed by a librarian,

which included subject headings and keywords. The search strategy had 3 main concepts

(disease, specimen type and outcome), and each concept was combined using the appropriate

Boolean operators. The search was tested against a sample set of known articles that were pre-

identified. The line-by-line search strategies for all databases are included in Supplementary

Tables 1-5. The search results were exported from each database and uploaded to the Covidence

online system for deduplication and screening.

Two authors independently screened titles and abstracts, reviewed full texts, collected data

and assessed risk of bias via Covidence and a hybrid critical appraisal checklist based on the

Joanna Briggs Institute (JBI) tools for case series, analytical cross-sectional studies and

prevalence studies[38-40]. To evaluate the sample size in a study, we used the following calculation:

450
$$n^* = \frac{z^2 \sigma}{d^2}, \tag{1}$$

where n^* is the sample size threshold, z is the z-score for the level of confidence (95%), σ is the

standard deviation (assumed to be 3 $\log_{10}$ copies/ml, one quarter of the full range of rVLs) and d

is the marginal error (assumed to be 1 $\log_{10}$ copies/ml, based on the minimum detection limit for

qRT-PCR across studies)[41]. The hybrid JBI critical appraisal checklist is shown in the

Supplementary Notes. Inconsistencies were resolved by discussion and consensus.

The search found 27 studies for COVID-19[13,35,42-66], 9 studies for SARS[67-75] and 27 studies

for A(H1N1)pdm09[76-102]. Quantitative specimen measurements were collected directly if

reported numerically or using WebPlotDigitizer 4.3 (https://apps.automeris.io/wpd/) if reported

graphically. For included studies, we also collected the relevant numbers of cases, types of cases,

volumes of transport media, pharmacotherapies, DFSO (for symptomatic cases) or day relative to

initial laboratory diagnosis (for asymptomatic cases) on which each specimen was taken and

numbers of tested specimens. Hospitalized cases were defined as those being tested in a hospital

setting and then admitted. Non-admitted cases were defined as those being testing in a hospital

setting but not admitted. Community cases were defined as those being tested in a community

setting. Symptomatic, presymptomatic and asymptomatic infections were defined as in the study.

Based on rare description in the included studies, paucisymptomatic infections, when defined in

a study, were included with symptomatic ones. Pediatric cases were defined as those of 18 years

of age or lower or as defined in the study. Adult cases were defined as those above 18 years of

age or as defined in the study.

Meta-analysis of rVLs

Based on the search design and composition of included studies, the meta-analysis overall

estimates were the expected SARS-CoV-2, SARS-CoV-1 and A(H1N1)pdm09 rVL when

encountering a COVID-19, SARS or A(H1N1)pdm09 case, respectively, during their infectious

period. To determine rVLs, data collected on positive, quantitative specimen measurements were

converted to the RNA concentration in the respiratory tract. Viral concentrations in respiratory

specimens were denoted as specimen measurements, whereas viral concentrations in the

respiratory tract were denoted as rVLs. For example, measurements from swabbed specimens

(NPS and OPS) typically report the RNA concentration in viral transport media. Based on the

expected uptake volume for swabs (0.128 ± 0.031 ml, mean ± SD)[103] or reported collection

volume for expulsed fluid in each study (e.g., 0.5 to 1 ml) along with the reported volume of

transport media in each study (e.g., 1 ml), we calculated the dilution factor for each respiratory

specimen to estimate the rVLs. If the diluent volume was not reported, then the dilution factor

was calculated assuming a volume of 1 ml (NPS and OPS), 2 ml (POS and ETA) or 3 ml (NPA)

of transport media[43,45,71]. Unless dilution was reported for Spu specimens, we used the specimen

measurement as the rVL[13]. The non-reporting of diluent volume was noted as an element

increasing risk of bias in the hybrid JBI critical appraisal checklist. Viral load estimates (based

on instrumentation, calibration, procedures and reagents) are not standardized. While the above

procedures (including only quantitative measurements after extraction, collecting assay detection

limits, correcting for specimen dilution) have considered many of these factors, non-

standardization is an inherent limitation in interpreting specimen measurements across studies.

Pooled estimates and 95% CIs for the expected rVL of each virus across their infectious

period were calculated using a random-effects meta-analysis. The estimates for rVL assumed

that each viral copy was extracted and quantified from the tested specimen aliquot. For studies

reporting summary statistics in medians and interquartile or total ranges, we derived estimates of

the mean and variance and calculated the 95% CIs[104]. All calculations were performed in units of

$\log_{10}$ copies/ml. Between-study heterogeneity in meta-analysis was assessed using the I^2 and τ^2

statistics. The weighting for each study in its virus group was calculated as the reciprocal of the

rVL variance.

Subgroup analyses of rVLs

Subgroup analyses were conducted to compare the expected rVLs of SARS-CoV-2 in adult,

pediatric, symptomatic and asymptomatic COVID-19 cases, as previously defined, during the

infectious period. The overall estimate for each subgroup was the expected rVL when

encountering a case of that subgroup during the infectious period. Studies reporting data

exclusively from a subgroup of interest were included in the analysis without modification. For

studies in which data for these subgroups constituted only part of its dataset, rVLs from the

subgroup were collected to calculate the mean, variance and 95% CIs. All calculations were

performed in units of $\log_{10}$ copies/ml. In the analysis, we excluded studies with only a single case

in our subgroups of interest. Pooled estimates and 95% CIs for each subgroup were calculated

using a random-effects meta-analysis, in which between-study heterogeneity was assessed using

the I^2 and τ^2 statistics. The weighting for each study in its subgroup was calculated as the

reciprocal of the rVL variance.

Distribution of rVL

To analyze heterogeneity in rVLs, we pooled the entirety of individual sample data (reported as

individual specimen measurements rather through descriptive statistics) in the systematic dataset

by disease, COVID-19 subgroups and DFSO. For analyses of SARS-CoV-2 dynamics across

DFSO, we included estimated rVLs from negative qRT-PCR measurements of respiratory

specimens (n=3, 3, 6, 8, 12, 15, 13, 17 and 14 negative specimens for 2, 3, 4, 5, 6, 7, 8, 9 and 10

DFSO, respectively) for cases that had previously been quantitatively confirmed to have

COVID-19. These rVLs were estimated based on the reported assay detection limit in the

respective study. Probability plots and modified Kolmogorov–Smirnov tests were used to

determine the suitability of normal, lognormal, gamma and Weibull distributions to describe the

distribution of rVLs for SARS-CoV-2, SARS-CoV-1 and A(H1N1)pdm09. For each virus, the

data best conformed to Weibull distributions, which is described by the probability density

function

$$528 \qquad f(v) = \frac{\alpha}{\beta}\left(\frac{v}{\beta}\right)^{\alpha-1} e^{-(v/\beta)^{\alpha}}, \qquad\qquad (2)$$

529   where α is the shape factor, β is the scale factor and v is rVL ($v \geq 0$ log$_{10}$ copies/ml). In this

530   distribution, the value of the rVL at the xth percentile was determined using the quantile function,

$$531 \qquad v_x = \beta[-\ln(1-x)]^{1/\alpha}. \qquad\qquad (3)$$

For cp curves, we used eq. (3) to determine rVLs from the 1$^{\text{st}}$ cp to the 99$^{\text{th}}$ cp (step size, 1%).

Curve fitting to eq. (2) and calculation of eq. (3) and its 95% CI was performed using the

Distribution Fitter application in Matlab R2019b (MathWorks, Inc., Natick, Massachusetts,

USA).

Meta-regression of k and heterogeneity in rVL

To assess the relationship between k and heterogeneity in rVL, we performed a univariate meta-

regression ($\log k = a(SD) + b$, where a is the slope for association and b is the intercept)

between pooled estimates of k (based on studies describing community transmission) for

COVID-19 (k=0.409)[4-6,105-108], SARS (k=0.165)[17] and A(H1N1)pdm09 (k=8.155)[22,23] and the SD

of the rVLs in each study. Since the negative binomial distribution, from which k is derived[17], is

analogous to a compound Poisson distribution in which each random variable is Log(k)-

distributed, the meta-regression was performed with log k. Based on negligible between-study

heterogeneity, we used a fixed-effects model. This analysis assumes that the SD of rVLs in each

study estimates SD of rVL for the disease. Thus, for weighting in the meta-regression, we used

the proportion of rVL samples for each study relative to the entire systematic dataset ($W_i =$

n_i/n_{total}). The regression line, its 95% CI and its Pearson correlation coefficient (r) were

presented along with the p-value for association (meta-regression slope t-test for a) between the

two variables. The meta-regression assumed that the viability proportion (for viruses exiting the

respiratory tract) was similar across cases for a given respiratory infection; it could be a different

value for different diseases. The meta-regression also assumed that the rate profile of particles

expelled by respiratory activities (e.g., talking) is similar among the diseases. The limit of

detection for qRT-PCR instruments used in the included studies did not significantly affect the

analysis of heterogeneity in rVL, as these limits tended to be below the values found for

specimens with low virus concentrations.

Viral kinetics

To model the kinetics of SARS-CoV-2 rVL, we used a mechanistic epithelial cell-limited model

for the respiratory tract[109], based on the system of differential equations:

561
$$\frac{dT}{dt} = -\beta TV \tag{4}$$

562
$$\frac{dI}{dt} = \beta TV - \delta I \tag{5}$$

563
$$\frac{dV}{dt} = pI - cV, \tag{6}$$

where T is the number of uninfected target cells, I is the number of productively infected cells, V

is the rVL, β is the infection rate constant, p is the rate at which airway epithelial cells shed virus

to the extracellular fluid, c is the clearance rate of the virus and δ is the clearance rate of

productively infected cells. Parameter units are summarized in Extended Data Table 3. Using

these parameters, the viral half-life in the respiratory tract ($t_{1/2} = \ln 2/c$) and the half-life of

productively infected cells ($t_{1/2} = \ln 2/\delta$) and their 95% CIs could be estimated. Moreover, the

cellular basic reproductive number (the expected number of secondary infected cells from a

single productively infected cell placed in a population of susceptible cells) was calculated by

572
$$R_{0,c} = \frac{p\beta T_0}{c\delta},$$
(7)

573 where T_0 is the initial number of susceptible cells[109].

574   For initial parameterization, eqs. (4)-(6) were simplified according to a quasi-steady state

575 approximation[110] to

576
$$\frac{dT}{dt} = -\beta TV$$
(8)

577
$$\frac{dV}{dt} = rTV - \delta V,$$
(9)

where $r = p\beta/c$, for a form with greater numerical stability. The system of differential equations

was fitted on the mean estimates of SARS-CoV-2 rVL between -2 and 10 DFSO using the

entirety of individual sample data in units of copies/ml. Numerical analysis was implemented

using the Fit ODE app in OriginPro 2019b (OriginLab Corporation, Northampton,

Massachusetts, USA) via the Runge-Kutta method and initial parameters V_0, I_0 and T_0 of 4

copies/ml, 0 cells and 5×10^7 cells, respectively, for the range -5 to 10 DFSO. The analysis was

first performed with eqs. (8)-(9). These output parameters were then used to initialize final

analysis using eqs. (4)-(6), where the estimates for β and δ were input as fixed and variable

parameters, respectively. The fitted line and its coefficient of determination (r^2) were presented.

To estimate the average incubation period, we extrapolated the kinetic model to 0 and 1

$\log_{10}$ copies/ml pre-symptom onset. To estimate the average duration of shedding, we

extrapolated the model to 0 $\log_{10}$ copies/ml post-symptom onset. Unlike experimental estimates,

this estimate for duration of shedding was not defined by assay detection limits. These analyses

had limitations. To estimate the average DFSO on which SARS-CoV-2 concentration reached

diagnostic levels, we extrapolated the model pre-symptom onset to the equivalent of 1 and 3

log$_{10}$ copies/ml in specimen concentration (chosen as example assay detection limits), as

described by the dilution factor estimation above. The average time from respiratory infection to

reach diagnostic levels was then calculated by subtracting these values from the incubation

period for 0 log$_{10}$ copies/ml. However, the extrapolated time for SARS-CoV-2 to reach

diagnostic concentrations in the respiratory tract should be validated in tracing studies, in which

contacts are prospectively subjected to daily sampling.

Considerations for particle dehydration

The desiccation time of a particle in air was described $t_{des} = b^{-1}(d_i^2 - d_{des}^2)$, where b is

prefactor for dehydration rate which depends on the environmental conditions, d_i is the initial

hydrated diameter and d_{des} is particle diameter after desiccation[111]. After desiccation, the

remaining non-volatile matter (ions, molecules, viruses and cells) governs particle size, which is

approximately 0.44 times the initial size of particles atomized in the respiratory tract[112].

Dehydrated aerodynamic diameter was calculated by $d_a = d_p(\rho/\rho_0)^{1/2}$, where d_p is the

dehydrated particle size, ρ is the material density of the respiratory particle and ρ_0 is the

reference material density (1 g/cm^3). For conservative estimates, the value of b was taken to be

64.9 µm^2/s[113] based on conditions of room temperature and a relative humidity of 59% (near the

upper limit of 60% for healthcare and typical indoor specifications)[114]. The equation for

desiccation time indicated that respiratory particles begin to dehydrate immediately upon release

to the ambient environment. Desiccation occurred rapidly, as the equation estimated that an 11.4-

µm particle desiccated to 5 µm in 1.6 s within the model conditions, and this value was an upper

limit for the desiccation times of aerosols ($t_{des} \leq 1.6$ s).

Likelihood of respiratory particles containing virions

617 To calculate an unbiased estimator for viral partitioning (the expected number of viable copies in

618 an expelled particle at a given size), we multiplied rVLs with the volume equation for spherical

619 particles during atomization and the estimated viability proportion:

$$\lambda = \frac{\pi \rho v_p \gamma \upsilon}{6} d^3, \tag{10}$$

where λ is the expectation value, ρ is the material density of the respiratory particle (997 g/m^3),

v_p is the volumetric conversion factor (1 ml/g), γ is the viability proportion, υ is the rVL and d is

the hydrated diameter of the particle during atomization. The model assumed γ was 0.1% for the

viruses. For influenza, approximately 0.1% of copies in particles expelled from the respiratory

tract represent viable virus[115], which is equivalent to one in 3 $\log_{10}$ copies/ml for rVL or, after

dilution in transport media, roughly one in 4 $\log_{10}$ copies/ml for specimen concentration. Recent

reports have detected culture-positive respiratory specimens with SARS-CoV-2 concentrations

down to 4 $\log_{10}$ copies/ml[13], including from pediatric patients[62] and in the presymptomatic

period[15], suggesting the assumption was also suitable for SARS-CoV-2.

Likelihood profiles were determined using Poisson statistics, as described by the probability

mass function

$$P(X = k) = \frac{\lambda^k e^{-\lambda}}{k!}, \tag{11}$$

633 where k is the number of virions partitioned within the particle. For λ, 95% CIs were determined

634 using the variance of its rVL estimate. To determine 95% CIs for likelihood profiles from the

635 probability mass function, we used the delta method, which specifies

$$\mathrm{Var}\big(g(\boldsymbol{\theta})\big) \approx \sigma^2 \dot{g}(\boldsymbol{\theta})' \mathbf{D} \dot{g}(\boldsymbol{\theta}), \tag{12}$$

637   where $\sigma^2 \mathbf{D}$ is the covariance matrix of $\boldsymbol{\theta}$ and $\dot{g}(\boldsymbol{\theta})$ is the gradient of $g(\boldsymbol{\theta})$. For the univariate

638   Poisson distribution, $\sigma^2 \mathbf{D} = \lambda$ and

639
$$\dot{g}(\theta) = \frac{\lambda^{k-1} e^{-\lambda}}{k!} (k - \lambda). \tag{13}$$

Based on the relative relationship between the residence time of expelled particles before

assessment (~5 s)[116] in the referenced study[115] and the estimated dehydration rates of expelled

particles, we took the viability proportion (0.1%) to be for dehydrated particles. The model

calculated partitioning of copies using the hydrated volume and then applied the viability

proportion for number of virions in particles after emission and dehydration. Thus, we compared

likelihoods among expelled, dehydrated particles. In Fig. 4, the comparison between hydrated

and dehydrated diameters showed only the relationship in particle size and not the relationship in

likelihood of containing viable virus. Based on the scope of the study, the model did not account

for the virion half-life as particles deposit onto surfaces or remain suspended in air[117].

Rate profiles of particles expelled by respiratory activities

For the rate profiles of particles expelled during respiratory activities, we used distributions from

the literature. For coughing, we considered the rate (particles/cough) of expelling particles at

different sizes, as determined by Loudon and Roberts[118], by calculating the mean number of

respiratory particles expelled per cough based on subject tests RI, RII, LI, LII and EI (EII was

presumed to be an outlier based on the relative rate when compared to EI). These particles were

taken to be dehydrated based on the deposition time in the experiment relative to estimated

dehydration rates. We compared this rate profile to that of Duguid[119], which were taken to be

hydrated particles based on experimental design. For talking, singing and breathing, we obtained

data from Morawaska et al[120]. Rate profiles (particles/min) were calculated by converting the

normalized concentration (particles/cm^3) at each particle size based on normalization (32

channels per decade) for the aerodynamic particle sizer (APS) used, unit conversion (cm^3 to L)

and the sample flow rate (1 L/min). Rate profiles of talking and singing were isolated from

breathing by subtracting the contribution of breathing to the combined data. Particles were taken

to be dehydrated based on the minimum particle age in the measurements. Based on the APS

used, the analyzed range for d_a was 0.3-20 μm. While larger droplets may potentially be expelled

by the respiratory activities, the data suggested that their emission rates were minimal, and there

was a limited bias associated with instrumentation. We compared these data for talking with rate

profiles of talking loudly and talking quietly from Asadi et al[121]. For data reported in a size

channel, we took the particle size to be the median value. Curves based on discrete particle

measurements were connected using the nonparametric Akima spline function.

Shedding virions via respiratory droplets and aerosols

To determine the respiratory shedding rate across particle size, rVL estimates and the hydrated

diameters of particles expelled by a respiratory activity were input into eq. (10), and the output

was then multiplied by the rate profile of the activity (talking, singing, breathing or coughing).

Dehydration and viability considerations were continued from the likelihood models. The model

used particle profiles from (coughing) Loudon and Roberts[118] or (talking, singing and breathing)

Morawaska et al[120].

To determine the total respiratory shedding rate for a given respiratory activity across cp, we

determined the cumulative hydrated volumetric rate (by summing the hydrated volumetric rates

across particle sizes for that respiratory activity) and input it into eq. (10). Using rVLs as

determined by the Weibull quantile functions, we then calculated the Poisson means and their

95% CIs at different cps.

To assess the relative contribution of aerosols and droplets to mediating respiratory viral

shedding for a given respiratory activity, we calculated the proportion of the cumulative hydrated

volumetric rate contributed by aerosols ($d_a{\leq}5$ μm) or droplets ($d_a{>}5$ μm) for that respiratory

activity. Since the Poisson mean was proportional to cumulative volumetric rate, this estimate of

the relative contribution of aerosols and droplets to respiratory viral shedding was consistent

among viruses and cps in the model.

In this study, the model for shedding virions via droplets and aerosols did not delineate

particles generated in the upper respiratory tract from those generated in the lower respiratory

tract, as the sites of atomization remain poorly understood. It also did not differentiate cases with

significant expectoration from those without it. In addition, it did not account for individual

variation in the profiles of expelled particles; superemitters can expel respiratory particles at

rates ~3 times above median[121].

Statistical analysis

For data collection, statistical analysis, coding and data visualization, we used Excel v16.40

(Microsoft Corporation, Redmond, Washington, USA), OriginPro 2019b (OriginLab

Corporation, Northampton, Massachusetts, USA) and Matlab R2019b (MathWorks, Inc., Natick,

Massachusetts, USA). Between-study heterogeneity in the random-effects meta-analyses was

assessed using the I^2 and τ^2 statistics. Probability plots for normal, lognormal, gamma and

Weibull distributions of rVLs were scored based on the Blom method. Modified Kolmogorov-

Smirnov tests were used to determine the goodness of fits between rVLs (in $\log_{10}$ copies/ml) and

normal, lognormal, gamma or Weibull distributions. By accepting the null hypothesis in the

modified Kolmogorov–Smirnov test, the given distribution cannot be rejected to fit the data.

Based on fitted Weibull distribution parameters, the Weibull quantile function was used to

determine the rVL and its 95% CIs at a given cp. The association between k and rVL was

assessed via meta-regression, and the p-value for association was based on the meta-regression

slope t-test. Likelihood profiles were determined using the Poisson probability mass function and

the unbiased estimator for the expected partitioning of virions at a given particle size. Variance

on likelihood estimates was determined via the delta method. Since case variance or sample size

may be unequal among the viral infections or subgroups, the two-sided Welch's t-test was used

to compare the difference of expected rVLs in the meta-analysis and subgroup analyses. For all

statistical analyses, the significance level (α) was taken to be 0.05.

Data availability

Data will be made available upon request. All raw data, code and model outputs from this study

will be made publicly available in online repositories after peer review. Search strategies for the

systematic review are shown in Supplementary Tables 1-5. The systematic review protocol was

prospectively registered on PROSPERO (registration number, CRD42020204637).

References (for Methods)

36   Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items

for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* **6**,

e1000097, doi:10.1371/journal.pmed.1000097 (2009).

37   Higgins, J. P. T. *et al. Cochrane Handbook for Systematic Reviews of Interventions*. (John
728   Wiley & Sons, 2019).

729   38   Munn, Z. *et al.* Methodological quality of case series studies: an introduction to the JBI
730   critical appraisal tool. *JBI Database System Rev Implement Rep*, doi:10.11124/JBISRIR-D-
731   19-00099 (2019).

732   39   Moola, S. *et al.* Chapter 7: Systematic reviews of etiology and risk. *JBI Manual for*
733   *Evidence Synthesis*. (The Joanna Briggs Institute, 2020).

734   40   Munn, Z., Moola, S., Lisy, K., Riitano, D. & Tufanaru, C. Methodological guidance for
735   systematic reviews of observational epidemiological studies reporting prevalence and
736   cumulative incidence data. *Int. J. Evid. Based Healthc.* **13**, 147-153,
737   doi:10.1097/XEB.0000000000000054 (2015).

738   41   Johnston, K. M., Lakzadeh, P., Donato, B. M. K. & Szabo, S. M. Methods of sample size
739   calculation in descriptive retrospective burden of illness studies. *BMC Med. Res. Methodol.*
740   **19**, 9, doi:10.1186/s12874-018-0657-9 (2019).

741   42   Zhang, N. *et al.* Comparative study on virus shedding patterns in nasopharyngeal and fecal
742   specimens of COVID-19 patients. *Sci China Life Sci*, doi:10.1007/s11427-020-1783-9
743   (2020).

744   43   Lavezzo, E. *et al.* Suppression of a SARS-CoV-2 outbreak in the Italian municipality of
745   Vo'. *Nature* **584**, 425-429, doi:10.1038/s41586-020-2488-1 (2020).

746   44   Peng, L. *et al.* SARS-CoV-2 can be detected in urine, blood, anal swabs, and
747   oropharyngeal swabs specimens. *J. Med. Virol.*, doi:10.1002/jmv.25936 (2020).

45   To, K. K. *et al.* Temporal profiles of viral load in posterior oropharyngeal saliva samples

and serum antibody responses during infection by SARS-CoV-2: an observational cohort

study. *Lancet Infect. Dis.* **20**, 565-574, doi:10.1016/S1473-3099(20)30196-1 (2020).

46   Zou, L. *et al.* SARS-CoV-2 viral load in upper respiratory specimens of infected patients.

N. Engl. J. Med. **382**, 1177-1179, doi:10.1056/NEJMc2001737 (2020).

47   Fajnzylber, J. M. *et al.* SARS-CoV-2 viral load is associated with increased disease

severity and mortality. Preprinted at medRxiv, doi:10.1101/2020.07.15.20131789 (2020).

48   Zheng, S. *et al.* Viral load dynamics and disease severity in patients infected with SARS-

CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ*

369, m1443, doi:10.1136/bmj.m1443 (2020).

49   Lennon, N. J. *et al.* Comparison of viral levels in individuals with or without symptoms at

time of COVID-19 testing among 32,480 residents and staff of nursing homes and assisted

living facilities in Massachusetts. Preprinted at medRxiv,

doi:10.1101/2020.07.20.20157792 (2020).

50   Shrestha, N. K. *et al.* Distribution of transmission potential during nonsevere COVID-19

illness. *Clin. Infect. Dis.*, doi:10.1093/cid/ciaa886 (2020).

51   Shi, F. *et al.* Association of viral load with serum biomakers among COVID-19 cases.

Virology **546**, 122-126, doi:10.1016/j.virol.2020.04.011 (2020).

52   Hung, I. F. *et al.* Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin

in the treatment of patients admitted to hospital with COVID-19: an open-label,

randomised, phase 2 trial. *Lancet* **395**, 1695-1704, doi:10.1016/S0140-6736(20)31042-4

(2020).

53   Iwasaki, S. *et al.* Comparison of SARS-CoV-2 detection in nasopharyngeal swab and

771   saliva. *J. Infect.* **81**, e145-e147, doi:10.1016/j.jinf.2020.05.071 (2020).

772   54   Perera, R. A. P. M. *et al.* SARS-CoV-2 virus culture from the upper respiratory tract:

773   Correlation with viral load, subgenomic viral RNA and duration of illness. Preprinted at

774   medRxiv, doi:10.1101/2020.07.08.20148783 (2020).

775   55   Baggio, S. *et al.* SARS-CoV-2 viral load in the upper respiratory tract of children and

776   adults with early acute COVID-19. *Clin. Infect. Dis.*, doi:10.1093/cid/ciaa1157 (2020).

777   56   Lucas, C. *et al.* Longitudinal analyses reveal immunological misfiring in severe COVID-

778   19. *Nature* **584**, 463-469, doi:10.1038/s41586-020-2588-y (2020).

779   57   Argyropoulos, K. V. *et al.* Association of initial viral load in severe acute respiratory

780   syndrome coronavirus 2 (SARS-CoV-2) patients with outcome and symptoms. *Am. J.*

781   *Pathol.* **190**, 1881-1887, doi:10.1016/j.ajpath.2020.07.001 (2020).

782   58   Mitja, O. *et al.* Hydroxychloroquine for early treatment of adults with mild Covid-19: a

783   randomized-controlled trial. *Clin. Infect. Dis.*, doi:10.1093/cid/ciaa1009 (2020).

784   59   Vetter, P. *et al.* Daily viral kinetics and innate and adaptive immune responses assessment

785   in COVID-19: a case series. Preprinted at medRxiv, doi:10.1101/2020.07.02.20143271

786   (2020).

787   60   Xu, Y. *et al.* Characteristics of pediatric SARS-CoV-2 infection and potential evidence for

788   persistent fecal viral shedding. *Nat. Med.* **26**, 502-505, doi:10.1038/s41591-020-0817-4

789   (2020).

790   61   Hurst, J. H. *et al.* SARS-CoV-2 infections among children in the biospecimens from

791   respiratory virus-exposed kids (BRAVE Kids) Study. Preprinted at medRxiv,

792   doi:10.1101/2020.08.18.20166835 (2020).

62   L'Huillier, A. G., Torriani, G., Pigny, F., Kaiser, L. & Eckerle, I. Culture-competent

SARS-CoV-2 in nasopharynx of symptomatic neonates, children, and adolescents. *Emerg.*

Infect. Dis. **26**, 2494-2497, doi:10.3201/eid2610.202403 (2020).

63   Han, M. S. *et al.* Viral RNA load in mildly symptomatic and asymptomatic children with

COVID-19, Seoul, South Korea. *Emerg. Infect. Dis.* **26**, 2497-2499,

doi:10.3201/eid2610.202449 (2020).

64   Pan, Y., Zhang, D., Yang, P., Poon, L. L. M. & Wang, Q. Viral load of SARS-CoV-2 in

clinical samples. *Lancet Infect. Dis.* **20**, 411-412, doi:10.1016/S1473-3099(20)30113-4

(2020).

65   Han, M. S. *et al.* Sequential analysis of viral load in a neonate and her mother infected with

SARS-CoV-2. *Clin. Infect. Dis.*, doi:10.1093/cid/ciaa447 (2020).

66   Kawasuji, H. *et al.* Viral load dynamics in transmissible symptomatic patients with

COVID-19. Preprinted at medRxiv, doi:10.1101/2020.06.02.20120014 (2020).

67   Chu, C. M. *et al.* Initial viral load and the outcomes of SARS. *CMAJ* **171**, 1349-1352,

doi:10.1503/cmaj.1040398 (2004).

68   Poon, L. L. *et al.* Early diagnosis of SARS coronavirus infection by real time RT-PCR. *J.*

Clin. Virol. **28**, 233-238, doi:10.1016/j.jcv.2003.08.004 (2003).

69   Chen, W. J. *et al.* Nasopharyngeal shedding of severe acute respiratory syndrome-

associated coronavirus is associated with genetic polymorphisms. *Clin. Infect. Dis.* **42**,

1561-1569, doi:10.1086/503843 (2006).

70   Chu, C. M. *et al.* Role of lopinavir/ritonavir in the treatment of SARS: initial virological

and clinical findings. *Thorax* **59**, 252-256, doi:10.1136/thorax.2003.012658 (2004).

71 Poon, L. L. *et al.* Detection of SARS coronavirus in patients with severe acute respiratory

syndrome by conventional and real-time quantitative reverse transcription-PCR assays.

Clin. Chem. **50**, 67-72, doi:10.1373/clinchem.2003.023663 (2004).

72 Chu, C. M. *et al.* Viral load distribution in SARS outbreak. *Emerg. Infect. Dis.* **11**, 1882-

1886, doi:10.3201/eid1112.040949 (2005).

73 Hung, I. F. *et al.* Viral loads in clinical specimens and SARS manifestations. *Emerg. Infect.*

Dis. **10**, 1550-1557, doi:10.3201/eid1009.040058 (2004).

74 Cheng, V. C. *et al.* Viral replication in the nasopharynx is associated with diarrhea in

patients with severe acute respiratory syndrome. *Clin. Infect. Dis.* **38**, 467-475,

doi:10.1086/382681 (2004).

75 Peiris, J. S. *et al.* Clinical progression and viral load in a community outbreak of

coronavirus-associated SARS pneumonia: a prospective study. *Lancet* **361**, 1767-1772,

doi:10.1016/s0140-6736(03)13412-5 (2003).

76 Loeb, M. *et al.* Longitudinal study of influenza molecular viral shedding in Hutterite

communities. *J. Infect. Dis.* **206**, 1078-1084, doi:10.1093/infdis/jis450 (2012).

77 Suess, T. *et al.* Shedding and transmission of novel influenza virus A/H1N1 infection in

households--Germany, 2009. *Am. J. Epidemiol.* **171**, 1157-1164, doi:10.1093/aje/kwq071

(2010).

78 Li, C. C. *et al.* Correlation of pandemic (H1N1) 2009 viral load with disease severity and

prolonged viral shedding in children. *Emerg. Infect. Dis.* **16**, 1265-1272,

doi:10.3201/eid1608.091918 (2010).

79   Lu, P. X. *et al.* Relationship between respiratory viral load and lung lesion severity: a study

in 24 cases of pandemic H1N1 2009 influenza A pneumonia. *J. Thorac. Dis.* **4**, 377-383,

doi:10.3978/j.issn.2072-1439.2012.08.02 (2012).

80   Ip, D. K. M. *et al.* The dynamic relationship between clinical symptomatology and viral

shedding in naturally acquired seasonal and pandemic influenza virus infections. *Clin.*

Infect. Dis. **62**, 431-437, doi:10.1093/cid/civ909 (2016).

81   Rath, B. *et al.* Virus load kinetics and resistance development during oseltamivir treatment

in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses.

Pediatr. Infect. Dis. J. **31**, 899-905, doi:10.1097/INF.0b013e31825c7304 (2012).

82   Meschi, S. *et al.* Duration of viral shedding in hospitalized patients infected with pandemic

H1N1. *BMC Infect. Dis.* **11**, 140, doi:10.1186/1471-2334-11-140 (2011).

83   Wu, U. I., Wang, J. T., Chen, Y. C. & Chang, S. C. Severity of pandemic H1N1 2009

influenza virus infection may not be directly correlated with initial viral load in upper

respiratory tract. *Influenza Other Respir. Viruses* **6**, 367-373, doi:10.1111/j.1750-

2659.2011.00300.x (2012).

84   Yang, J. R., Lo, J., Ho, Y. L., Wu, H. S. & Liu, M. T. Pandemic H1N1 and seasonal H3N2

influenza infection in the human population show different distributions of viral loads,

which substantially affect the performance of rapid influenza tests. *Virus Res.* **155**, 163-

167, doi:10.1016/j.virusres.2010.09.015 (2011).

85   Launes, C. *et al.* Viral load at diagnosis and influenza A H1N1 (2009) disease severity in

children. *Influenza Other Respir. Viruses* **6**, e89-92, doi:10.1111/j.1750-

2659.2012.00383.x (2012).

858 86 Killingley, B. *et al.* Virus shedding and environmental deposition of novel A (H1N1)

859   pandemic influenza virus: interim findings. *Health Technol. Assess.* **14**, 237-354,

860   doi:10.3310/hta14460-04 (2010).

861 87 Lee, N. *et al.* Viral clearance and inflammatory response patterns in adults hospitalized for

862   pandemic 2009 influenza A(H1N1) virus pneumonia. *Antivir. Ther.* **16**, 237-247,

863   doi:10.3851/IMP1722 (2011).

864 88 Chan, P. K. *et al.* Clinical and virological course of infection with haemagglutinin D222G

865   mutant strain of 2009 pandemic influenza A (H1N1) virus. *J. Clin. Virol.* **50**, 320-324,

866   doi:10.1016/j.jcv.2011.01.013 (2011).

867 89 Hung, I. F. *et al.* Effect of clinical and virological parameters on the level of neutralizing

868   antibody against pandemic influenza A virus H1N1 2009. *Clin. Infect. Dis.* **51**, 274-279,

869   doi:10.1086/653940 (2010).

870 90 To, K. K. *et al.* Delayed clearance of viral load and marked cytokine activation in severe

871   cases of pandemic H1N1 2009 influenza virus infection. *Clin. Infect. Dis.* **50**, 850-859,

872   doi:10.1086/650581 (2010).

873 91 Thai, P. Q. *et al.* Pandemic H1N1 virus transmission and shedding dynamics in index case

874   households of a prospective Vietnamese cohort. *J. Infect.* **68**, 581-590,

875   doi:10.1016/j.jinf.2014.01.008 (2014).

876 92 Ito, M. *et al.* Detection of pandemic influenza A (H1N1) 2009 virus RNA by real-time

877   reverse transcription polymerase chain reaction. *Pediatr. Int.* **54**, 959-962,

878   doi:10.1111/j.1442-200X.2012.03720.x (2012).

93   Li, I. W. *et al.* The natural viral load profile of patients with pandemic 2009 influenza

A(H1N1) and the effect of oseltamivir treatment. *Chest* **137**, 759-768,

doi:10.1378/chest.09-3072 (2010).

94   Esposito, S. *et al.* Viral shedding in children infected by pandemic A/H1N1/2009 influenza

virus. *Virol J.* **8**, 349, doi:10.1186/1743-422X-8-349 (2011).

95   Lee, C. K. *et al.* Comparison of pandemic (H1N1) 2009 and seasonal influenza viral loads,

Singapore. *Emerg. Infect. Dis.* **17**, 287-291, doi:10.3201/eid1702.100282 (2011).

96   Cowling, B. J. *et al.* Comparative epidemiology of pandemic and seasonal influenza A in

households. *N. Engl. J. Med.* **362**, 2175-2184, doi:10.1056/NEJMoa0911530 (2010).

97   To, K. K. *et al.* Viral load in patients infected with pandemic H1N1 2009 influenza A

virus. *J. Med. Virol.* **82**, 1-7, doi:10.1002/jmv.21664 (2010).

98   Alves, V. R. G. *et al.* Influenza A(H1N1)pdm09 infection and viral load analysis in

patients with different clinical presentations. *Mem. Inst. Oswaldo Cruz* **115**, e200009,

doi:10.1590/0074-02760200009 (2020).

99   Cheng, P. K. *et al.* Performance of laboratory diagnostics for the detection of influenza

A(H1N1)v virus as correlated with the time after symptom onset and viral load. *J. Clin.*

Virol. **47**, 182-185, doi:10.1016/j.jcv.2009.11.022 (2010).

100   Ngaosuwankul, N. *et al.* Influenza A viral loads in respiratory samples collected from

patients infected with pandemic H1N1, seasonal H1N1 and H3N2 viruses. *Virol J.* **7**, 75,

doi:10.1186/1743-422X-7-75 (2010).

101   Duchamp, M. B. *et al.* Pandemic A(H1N1)2009 influenza virus detection by real time RT-

PCR: is viral quantification useful? *Clin. Microbiol. Infect.* **16**, 317-321,

doi:10.1111/j.1469-0691.2010.03169.x (2010).

102   Watanabe, M., Nukuzuma, S., Ito, M. & Ihara, T. Viral load and rapid diagnostic test in

903   patients with pandemic H1N1 2009. *Pediatr. Int.* **53**, 1097-1099, doi:10.1111/j.1442-

904   200X.2011.03489.x (2011).

905   103   Warnke, P., Warning, L. & Podbielski, A. Some are more equal - a comparative study on

906   swab uptake and release of bacterial suspensions. *PLoS One* **9**, e102215,

907   doi:10.1371/journal.pone.0102215 (2014).

908   104   Wan, X., Wang, W., Liu, J. & Tong, T. Estimating the sample mean and standard deviation

909   from the sample size, median, range and/or interquartile range. *BMC Med. Res. Methodol.*

910   **14**, 135, doi:10.1186/1471-2288-14-135 (2014).

911   105   Adam, D. C. *et al.* Clustering and superspreading potential of SARS-CoV-2 infections in

912   Hong Kong. *Nat. Med.*, doi:10.1038/s41591-020-1092-0 (2020).

913   106   Riou, J. & Althaus, C. L. Pattern of early human-to-human transmission of Wuhan 2019

914   novel coronavirus (2019-nCoV), December 2019 to January 2020. *Euro Surveill.* **25**,

915   doi:10.2807/1560-7917.ES.2020.25.4.2000058 (2020).

916   107   Zhang, Y., Li, Y., Wang, L., Li, M. & Zhou, X. Evaluating transmission heterogeneity and

917   super-spreading event of COVID-19 in a metropolis of China. *Int. J. Environ. Res. Public*

918   *Health* **17**, doi:10.3390/ijerph17103705 (2020).

919   108   Tariq, A. *et al.* Real-time monitoring the transmission potential of COVID-19 in

920   Singapore, March 2020. *BMC Med.* **18**, 166, doi:10.1186/s12916-020-01615-9 (2020).

921   109   Baccam, P., Beauchemin, C., Macken, C. A., Hayden, F. G. & Perelson, A. S. Kinetics of

922   influenza A virus infection in humans. *J. Virol.* **80**, 7590-7599, doi:10.1128/JVI.01623-05

923   (2006).

110   Ikeda, H. *et al.* Quantifying the effect of Vpu on the promotion of HIV-1 replication in the

humanized mouse model. *Retrovirology* **13**, 23, doi:10.1186/s12977-016-0252-2 (2016).

111   Wells, W. F. On air-borne infection: study II. droplets and droplet nuclei. *Am. J.*

Epidemiol. **20**, 611-618, doi:10.1093/oxfordjournals.aje.a118097 (1934).

112   Nicas, M., Nazaroff, W. W. & Hubbard, A. Toward understanding the risk of secondary

airborne infection: emission of respirable pathogens. *J. Occup. Environ. Hyg.* **2**, 143-154,

doi:10.1080/15459620590918466 (2005).

113   Stadnytskyi, V., Bax, C. E., Bax, A. & Anfinrud, P. The airborne lifetime of small speech

droplets and their potential importance in SARS-CoV-2 transmission. *Proc. Natl. Acad.*

Sci. U. S. A. **117**, 11875-11877, doi:10.1073/pnas.2006874117 (2020).

114   Institute, T. F. G. *Guidelines for design and construction of health care facilities*. (The

American Institute of Architects, 2006).

115   Yan, J. *et al.* Infectious virus in exhaled breath of symptomatic seasonal influenza cases

from a college community. *Proc. Natl. Acad. Sci. U. S. A.* **115**, 1081-1086,

doi:10.1073/pnas.1716561115 (2018).

116   McDevitt, J. J. *et al.* Development and performance evaluation of an exhaled-breath

bioaerosol collector for influenza virus. *Aerosol Sci. Technol.* **47**, 444-451,

doi:10.1080/02786826.2012.762973 (2013).

117   van Doremalen, N. *et al.* Aerosol and surface stability of SARS-CoV-2 as compared with

SARS-CoV-1. *N. Engl. J. Med.* **382**, 1564-1567, doi:10.1056/NEJMc2004973 (2020).

118   Loudon, R. G. & Roberts, R. M. Droplet expulsion from the respiratory tract. *Am. Rev.*

Respir. Dis. **95**, 435-442, doi:10.1164/arrd.1967.95.3.435 (1967).

119 Duguid, J. P. The size and the duration of air-carriage of respiratory droplets and droplet-

nuclei. *J. Hyg. (Lond.)* **44**, 471-479, doi:10.1017/s0022172400019288 (1946).

120 Morawska, L. *et al.* Size distribution and sites of origin of droplets expelled from the

human respiratory tract during expiratory activities. *J. Aerosol Sci* **40**, 256-269,

doi:10.1016/j.jaerosci.2008.11.002 (2009).

121 Asadi, S. *et al.* Aerosol emission and superemission during human speech increase with

voice loudness. *Sci. Rep.* **9**, 2348, doi:10.1038/s41598-019-38808-z (2019).

Acknowledgements

We thank T. Alba (Toronto) for discussion on statistical methods. We thank E. Lavezzo and A.

Chrisanti (Padova) for responses to data inquiries. This work was supported by the Natural

Sciences and Engineering Research Council of Canada (NSERC) and the Toronto COVID-19

Action Fund. P.Z.C. was supported by the NSERC Vanier Scholarship (608544). D.N.F. was

supported by the Canadian Institutes of Health Research (Canadian COVID-19 Rapid Research

Fund, OV4-170360). F.X.G. was supported by the NSERC Senior Industrial Research Chair.

Author contributions

P.Z.C. designed the study, performed analyses, interpreted results and drafted the manuscript.

P.Z.C. and N.B. conducted screening, appraised studies and drafted the review protocol. Z.P.

developed and conducted the systematic review search. M.K. and D.N.F. assessed methods,

interpreted results and contributed to the discussion. All authors reviewed and revised the

manuscript. F.X.G. secured funds, interpreted results and supervised the project.

Competing interests The authors declare no competing interests.

Supplementary information is available for this paper.

Correspondence and requests for materials should be addressed to F.X.G.

Subgroup, study ref.	Cases		Specimens			Respiratory viral load, log₁₀ copies/ml (95% CI)	p-value for difference
	No.	Type	No.	DFSO	Type		
SARS-CoV-2							
42	4	H, A, S	9	4 to 10	NPS, OPS	4.12 (3.18-5.05)	
43	102	H, C, A, P, S, Ps, As	109	-2 to 10	NPS, OPS	4.63 (4.34-4.92)	
44	6	H, A, S	6	3 to 8	OPS	5.13 (4.83-5.42)	
45	23	H, A, S	51	0 to 10	ETA, POS	5.29 (4.65-5.93)	
46	14	H, A, S, As	55	0 to 10	NPS, OPS	5.30 (4.87-5.74)	
47	-	H, N, A, S	31	2 to 10	NPS, OPS, Spu	5.41 (4.81-6.01)	
61	133	C, A, P, S, Ps, As	133	-3 to 10	NPS	5.59 (5.31-5.88)	
48	-	H, A, S	19	1 to 10	POS, Spu	5.62 (5.22-6.03)	
60	7	H, P, S, Ps, As	14	-1 to 10	NPS	5.69 (5.26-6.12)	
64	75	H, S, Ps	104	-1 to 8	OPS, Spu	5.98 (5.31-6.66)	
49	2,200	C, A, P, As	2,200	0	NPS	6.01 (5.93-6.09)	
50	171	N, A, S	171	0 to 10	NPS	6.07 (5.79-6.34)	
51	103	H, N, A, S	103	0 to 8	NPS, OPS	6.10 (5.98-6.23)	
13	9	H, A, S, As	133	2 to 10	NPS, OPS, Spu	6.21 (5.90-6.52)	
52	41	H, A, S	310	2 to 10	NPS, OPS, POS	6.28 (6.05-6.50)	
53	5	H, A, S	5	7 to 9	NPS	6.48 (5.26-7.70)	
54	-	H, A, S, As	38	0 to 9	NPA, NPS, OPS, Spu	6.52 (5.77-7.27)	
66	16	H, A, P, S, Ps, As	17	-1 to 10	NPS	6.77 (5.96-7.58)	
55	405	H, A, P, S	405	0 to 5	NPS	6.95 (6.78-7.17)	
62	23	H, P, S	23	0 to 4	NPS	7.20 (6.23-8.16)	
56	24	H, A, S	33	0 to 10	NPS	7.51 (6.97-8.05)	
57	205	H, N, A, S	205	0 to 10	NPS	7.55 (7.30-7.81)	
35	-	H, A, S	154	0 to 10	NPS, Spu	7.83 (7.58-8.08)	
65	2	H, A, P, S	8	4 to 10	NPS, OPS	7.91 (6.69-9.12)	
58	148	N, A, S	296	1 to 8	NPS	8.04 (7.81-8.28)	
63	12	H, P, S, As	27	0 to 10	NPS	8.07 (7.47-8.67)	
59	5	H, A, S	63	0 to 10	NPS, OPS	8.34 (7.95-8.73)	
Overall (Q₂₆ = 13.2, p = 0.98, I² = 0.0%)						6.21 (6.10-6.31)	-
SARS-CoV-1							
67	133	H, A, S	133	1 to 7	NPA	2.89 (2.24-3.55)	
68	40	H, A, S	40	1 to 3	NPA	4.18 (3.24-5.12)	
69	153	H, A, S	153	0 to 19	NPS	4.90 (4.64-5.16)	
70	11	H, A, S	11	20	NPS	5.09 (3.60-6.59)	
71	-	H, A, S	43	1 to 10	NPA	5.62 (4.94-6.30)	
72	57	H, A, S	57	0 to 6	NPA	5.86 (5.36-6.35)	
73	60	H, A, S	60	10 to 15	NPA	6.65 (6.21-7.08)	
74	59	H, A, S	59	10	NPA	6.67 (6.23-7.11)	
75	14	H, A, S	42	5 to 15	NPA	6.73 (6.28-7.18)	
Overall (Q₈ = 2.16, p = 0.98, I² = 0.0%)						5.85 (5.42-6.28)	0.148
Influenza A(H1N1)pdm09							
76	97	C, A, P, S, Ps, As	218	-2 to 9	NPS	5.10 (4.93-5.27)	
77	51	C, A, P, S, As	129	1 to 7	NPA, NPS, OPS	5.17 (4.85-5.49)	
78	581	H, A, P, S	581	1 to 8	OPS	5.46 (5.38-5.55)	
79	13	H, A, P, S	25	2 to 9	NPS	5.69 (4.97-6.41)	
80	17	C, A, P, S	20	0 to 6	NPS, OPS	5.73 (5.17-6.29)	
81	27	H, P, S	41	2 to 7	NPS	5.84 (5.41-6.27)	
82	533	H, A, S	533	0 to 9	NPS	6.09 (5.98-6.20)	
83	64	H, N, A, P, S	89	1 to 7	NPS	6.18 (5.79-6.58)	
84	633	H, N, A, P, S	533	0 to 3	OPS	6.31 (6.07-6.56)	
85	47	H, P, S	47	1 to 4	NPA	6.49 (6.01-6.98)	
86	12	H, C, A, P, S	21	3 to 5	NPS	6.83 (6.16-7.51)	
87	48	H, A, S	48	0 to 7	NPA	6.84 (6.44-7.23)	
88	58	H, A, S	58	0 to 9	NPA, NPS, OPS	6.86 (6.52-7.20)	
89	87	H, N, A, P, S	87	0 to 7	NPA, NPS	6.87 (6.60-7.15)	
90	50	H, A, S	50	0 to 9	NPA, NPS	7.04 (6.51-7.58)	
91	33	C, A, P, S, Ps, As	123	-1 to 8	NPS, OPS	7.16 (6.95-7.37)	
92	34	H, A, P, S	34	0 to 2	NPS	7.18 (6.77-7.59)	
93	27	H, A, P, S	59	0 to 7	NPA, NPS, OPS	7.21 (6.83-7.58)	
94	74	H, P, S	282	1 to 9	NPS	7.22 (6.99-7.44)	
95	578	H, A, P, S	578	1 to 7	NPS	7.22 (7.11-7.34)	
96	45	N, C, A, P, S	54	0 to 8	NPS, OPS	7.28 (6.85-7.71)	
97	22	H, A, P, S	22	0 to 7	NPA, NPS, OPS	7.29 (6.53-8.05)	
98	86	N, C, A, P, S, As	86	0 to 8	NPA, NPS, OPS	7.32 (6.94-7.71)	
99	60	H, A, P, S	60	0 to 3	NPA	7.38 (6.98-7.78)	
100	12	H, A, P, S	33	2 to 9	NPA, NPS, OPS	7.39 (6.81-7.97)	
101	209	H, C, P, S	209	0 to 7	NPS	8.21 (8.06-8.36)	
102	251	H, P, S	251	0 to 2	NPA	8.42 (8.28-8.56)	
Overall (Q₂₆ = 9.53, p > 0.99, I² = 0.0%)						6.72 (6.61-6.83)	<0.0001

2 3 4 5 6 7 8 9

Extended Data Fig. 1. Meta-analysis of respiratory viral loads of SARS-CoV-2, SARS-CoV-1 and influenza A(H1N1)pdm09 during the infectious period. Random-effects meta-analyses comparing the expected rVLs for COVID-19, SARS and A(H1N1)pdm09 cases during the infectious period. Quantitative specimen measurements were used to estimate rVLs, which refer to virus concentrations in the respiratory tract. Case types: hospitalized (H), not admitted (N), community (C), adult (A), pediatric (P), symptomatic (S), presymptomatic (Ps) and asymptomatic (As). Specimen types: endotracheal aspirate (ETA), nasopharyngeal aspirate (NPA), nasopharyngeal swab (NPS), oropharyngeal swab (OPS), posterior oropharyngeal saliva (POS) and sputum (Spu). Studies after ref. 35 are listed in Methods. Dashes denote case numbers that were not obtained. Box sizes are proportional to weighting in the overall estimates. Two-sided Welch's t-test (relative to SARS-CoV-2), non-significance ($p>0.05$).

Extended Data Fig. 2. Respiratory viral loads for SARS-CoV-2, SARS-CoV-1 and A(H1N1)pdm09 best conform to Weibull distributions. a-d, Normal ($p{\leq}0.01$) (**a**), lognormal ($p{\leq}0.01$) (**b**), gamma ($p{\leq}0.005$) (**c**) and Weibull ($p{>}0.10$, not significant [NS]) (**d**) probability

plots for individual sample data of SARS-CoV-2 rVLs across DFSO in the systematic dataset

(*n*=916 samples from *n*=19 studies). **e-h**, Normal (*p*>0.10, NS) (**e**), lognormal (*p*≤0.01) (**f**),

gamma (*p*>0.05, NS) (**g**) and Weibull (*p*>0.10, NS) (**h**) probability plots for individual sample

data of SARS-CoV-1 rVLs in the systematic dataset (*n*=303 samples from *n*=5 studies). **i-l**,

Normal (*p*≤0.01) (**i**), lognormal (*p*≤0.01) (**j**), gamma (*p*≤0.005) (**k**) and Weibull (*p*>0.10, NS) (**l**)

probability plots for individual sample data of A(H1N1)pdm09 rVLs in the systematic dataset

(*n*=512 samples from *n*=10 studies). These categories included only rVL data from positive

(above the detection limit) qRT-PCR measurements. The *p*-values were determined using the

modified Kolmogorov-Smirnov test for the goodness of fit of the distributions. When the null

hypothesis is accepted (NS at *p*>0.05), the probability density function cannot be rejected to

describe the distribution of the data. Blue circles, black lines and red lines represent individual

sample data, expected distributions and 95% CIs, respectively. **m-o**, Histograms and fitted

Weibull distributions of the above data for SARS-CoV-2 (**m**), SARS-CoV-1 (**n**) and

A(H1N1)pdm09 (**o**).

1004

Extended Data Fig. 3. Respiratory viral loads across case percentiles for viruses, subgroups and days from symptom onset. a, b, Estimated rVLs of SARS-CoV-2 (**a**), SARS-CoV-1 (**b**) and A(H1N1)pdm09 (**c**) across cp during the infectious periods. **d-g**, Estimated SARS-CoV-2 rVLs across cp for adult (**d**), pediatric (**e**), symptomatic/presymptomatic (**f**) and asymptomatic (**g**) cases during the infectious period. **h-s**, Estimated SARS-CoV-2 rVLs across cp on different days of the infectious period. Earlier presymptomatic days were excluded based on limited data. Data ranged between the 1st and 99th cps. Sample numbers, distribution parameters and descriptive statistics are summarized in Extended Data Table 2. Lines and bands represent estimates and 95% CIs, respectively.

Extended Data Fig. 4. Rate profiles for particle expelled by respiratory activities. a,b, Rate profiles of particles expelled during coughing. The data were obtained from Loudon and Roberts[118] (**a**) and Duguid[119] (**b**). **c**, Rate profile of particles expelled during singing, as obtained from Morawaska et al[120]. **d,e**, Rate profiles of particles expelled during talking. The data were obtained from Asadi et al[121] (**d**) and Morawaska et al[120]. (**e**). **f**, Rate profiles of particles expelled during breathing at a natural pace, as obtained from Morawaska et al[120]. Insets, particle profiles with a logarithmic axis for diameter during atomization.

1022

Extended Data Fig. 5. Heterogeneity in shedding SAR-CoV-2 via talking, breathing and

coughing. a-c, Case heterogeneity in the total SARS-CoV-2 shedding rate (over all particle

sizes) by talking at a moderate level (**a**), breathing (**b**) or coughing (**c**) for COVID-19 cases

across the infectious period. Earlier presymptomatic days were excluded based on limited data.

Data represent estimated rates for viable virus and range between the 1st and 99th cps. Lines and

bands represent estimates and 95% CIs, respectively.

Extended Data Fig. 6. Heterogeneity in respiratory virus shedding for subgroup COVID-

19, SARS and A(H1N1)pdm09 cases. a-d, Case heterogeneity in the total SARS-CoV-2

shedding rate for adult (**a**), pediatric (**b**), symptomatic/presymptomatic (**c**) and asymptomatic (**d**)

COVID-19 cases via talking, singing, breathing and coughing during the infectious period. **e,f**,

Case heterogeneity in the total SARS-CoV-1 (**e**) and A(H1N1)pdm09 (**f**) shedding rates via

talking, singing, breathing and coughing for SARS and A(H1N1)pdm09 cases, respectively,

during the infectious periods. Data represent estimated rates for viable virus and range between

the 1st and 99th cps. Lines and bands represent estimates and 95% CIs, respectively.

1038

Extended Data Table 1 | Characteristics of included studies

Study*	Country	No. of cases included (no. of specimens)	No. of pediatric cases (no. of specimens)	No. of asymptomatic cases (no. of specimens)	Disease caused by virus	Case definition (WHO)	Pharmaco-therapy (type)[†]	Individual data extracted (diluent volume reported)[‡]	Adjusted viral load[§] (type of specimen)	Weight, % (meta-analysis category)[∥]	Weight, % (meta-regression)	Risk of bias[¶]
Argyropoulos et al. (2020)[57]	USA	205 (205)	0	0	COVID-19	Confirmed	No	No (no)	Yes (NPS)	2.3 (V), 2.9 (A), 2.5 (S/Ps)	2.12	********
Baggio et al. (2020)[55]	Switzerland	405 (405)	58 (58)	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	2.1 (V), 2.7 (A), 11.5 (P), 2.2 (S/Ps)	4.18	*******
Fajnzylber et al. (2020)[47]	USA	- (31)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS) No (Spu)	2.8 (V), 3.5 (A), 3.0 (S/Ps)	0.32	********
Han et al. (2020)[65]	South Korea	2 (8)	1 (6)	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	2.7 (V), 2.8 (S/Ps)	0.08	******
Han et al. (2020)[63]	South Korea	12 (27)	12 (27)	3 (7)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	3.2 (V), 18.5 (P), 3.2 (S/Ps), 31.0 (As)	0.28	********
Hung et al. (2020)[52]	China	41 (310)	0	0	COVID-19	Confirmed	No (control group)	No (no)	Yes (NPS, OPS, POS)	2.0 (V), 2.4 (A), 2.1 (S)	3.20	********
Hurst et al. (2020)[61]	USA	133 (133)	54 (54)	52 (52)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	2.8 (V), 15.3 (P), 3.0 (S/Ps), 24.1 (As)	1.37	********
Iwasaki et al. (2020)[53]	Japan	5 (5)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	4.2 (V), 5.2 (A), 4.5 (S/Ps)	0.05	***
Kawasuji et al. (2020)[66]	Japan	16 (16)	-	-	COVID-19	Confirmed	Yes (antivirals - type not reported)	Yes (no)	Yes (NPS)	2.8 (V)	0.18	*****
L'Huillier et al. (2020)[62]	Switzerland	23 (23)	23 (23)	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	1.5 (V), 8.4 (P), 1.6 (S/Ps)	0.24	********
Lavezzo et al. (2020)[43]	Italy	103 (110)	2 (3)	49 (49)	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS)	3.2 (V), 4.0 (A), 14.4 (P), 3.3 (S/Ps), 27.9 (A)	1.13	*******
Lennon et al. (2020)[49]	USA	2,200 (2,200)	18 (18)	2,200 (2,200[#])	COVID-19	Confirmed	No	No (yes)	Yes (NPS)	2.0 (V), 2.5 (A), 17.0 (As)	22.70	********
Lucas et al. (2020)[56]	USA	24 (33)	0	0	COVID-19	Confirmed	Moderate and severe patients (tocilizumab)	Yes (yes)	Yes (NPS)	3.3 (V), 4.0 (A), 3.5 (S/Ps)	0.34	*******
Mitja et al. (2020)[58]	Spain	148 (296)	0	0	COVID-19	Confirmed	No (control group)	No (no)	Yes (NPS)	1.9 (V), 2.3 (A), 2.0 (S/Ps)	3.05	********
Pan et al. (2020)[64]	China	75 (104)	-	0	COVID-19	Confirmed	No	Yes (no)	Yes (OPS) No (Spu)	0.7 (V), 0.7 (S/Ps)	1.07	****

Peng et al. (2020)[44]	China	6 (6)	0	0	COVID-19	Confirmed	Yes (arbidol, lopinavir, ritonavir)	Yes (no)	Yes (OPS)	6.6 (V), 8.2 (A), 7.1 (S/Ps)	0.06	********
Perera et al. (2020)[54]	China	- (36)	0	-	COVID-19	Confirmed	No	Yes (no)	Yes (NPA, NPS, OPS, Spu)	1.5 (V), 1.8 (A)	0.39	****
Shi et al. (2020)[51]	China	103 (103)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	19.0 (V), 23.4 (A), 20.2 (S/Ps)	1.06	*****
Shrestha et al. (2020)[50]	USA	171 (171)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	2.4 (V), 3.0 (A), 2.6 (S/Ps)	1.76	*******
To et al. (2020)[45]	China	23 (51)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (ETA, POS)	1.5 (V), 1.8 (A), 1.6 (S/Ps)	0.53	*********
van Kampen et al. (2020)[35]	The Netherlands	- (154)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, Spu)	3.2 (V), 4.0 (A), 3.5 (S/Ps)	1.59	*******
Vetter et al. (2020)[59]	Switzerland	5 (63)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS)	3.3 (V), 4.1 (A), 3.5 (S/Ps)	0.65	*********
Wölfel et al. (2020)[13]	Germany	9 (136)	0	1 (4)	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS) No (Spu)	2.5 (V), 3.0 (A), 3.2 (S)	1.37	*******
Xu et al. (2020)[60]	China	7 (14)	7 (14)	1 (1)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	5.5 (V), 31.8 (P), 5.8 (S/Ps),	0.14	********
Zhang et al. (2020)[42]	China	9 (9)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	4.0 (V), 5.0 (A), 4.3 (S/Ps)	0.09	********
Zheng et al. (2020)[48]	China	- (19)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (POS, Spu)	10.0 (V), 12.4 (A), 10.7 (S/Ps)	0.20	*******
Zou et al. (2020)[46]	China	14 (55)	0	1 (4)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	3.0 (V), 3.7 (A), 3.1 (S/Ps)	0.57	********
Chen et al. (2006)[69]	China	154 (154#)	0	0	SARS	Confirmed	Yes (oseltamivir, broad-spectrum antibiotics, ribavirin)	Yes (no)	Yes (NPS)	17.9 (V)	1.58	********
Chu et al. (2004)[67]	China	133 (133)	0	0	SARS	Confirmed	No	No (yes)	Yes (NPA)	2.9 (V)	1.37	*********
Chu et al. (2004)[70] ☆	China	11 (11)	0	0	SARS	Confirmed	No (control group)	Yes (yes)	Yes (NPS)	6.7 (V)	0.11	*********
Chu et al. (2005)[72]	China	57 (57)	0	0	SARS	Confirmed	No	Yes (yes)	Yes (NPA)	11.6 (V)	0.59	*********
Cheng et al. (2004)[74]	China	59 (59)	0	0	SARS	Confirmed	Yes (ribavirin, hydrocortisone, prednisolone, methylpredni-solone)	Yes (yes)	Yes (NPA)	14.2 (V)	0.61	********
Hung et al. (2004)[73]	China	60 (60)	0	0	SARS	Confirmed	Yes (ribavirin, hydrocortisone, prednisolone,	No (yes)	Yes (NPA)	14.7 (V)	0.62	*******

Study	Country				Pathogen		Treatment		Sample	Value		
							methylpredni-solone)					
Peiris et al. (2003)[75] ☆	China	14 (42)	0	0	SARS	Confirmed	Yes (ribavirin, hydrocortisone, prednisolone, methylpredni-solone)	Yes (no)	Yes (NPA)	19.2 (V)	0.43	********
Poon et al. (2003)[68]	China	40 (40)	0	0	SARS	Confirmed	No	No (yes)	Yes (NPA)	4.6 (V)	0.41	*****
Poon et al. (2004)[71]	China	- (43)	0	0	SARS	Confirmed	-	No (yes)	Yes (NPA)	8.2 (V)	0.44	*****
Alves et al. (2020)[98]	Brazil	86 (86)	-	15 (15)	Influenza A(H1N1)pdm09	Confirmed	No	No (yes)	Yes (NPA, NPS, OPS)	2.4 (V)	0.89	*****
Chan et al. (2011)[88]	China	58 (58)	0	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	Yes (no)	Yes (NPA, NPS, OPS)	4.6 (V)	0.60	******
Cheng et al. (2010)[99]	China	60 (60)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA)	3.3 (V)	0.62	******
Cowling et al. (2010)[96]	China	45 (54)	22 (31)	0	Influenza A(H1N1)pdm09	Confirmed	Yes (22 cases on oseltamivir)	Yes (yes)	Yes (NPS, OPS)	3.1 (V)	0.56	*******
Duchamp et al. (2010)[101]	France	209 (209)	209 (209)	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir, zanamivir)	No (yes)	Yes (NPS)	2.4 (V)	2.16	*****
Esposito et al. (2011)[94]	Italy	74 (282)	74 (282)	0	Influenza A(H1N1)pdm09	Confirmed	No	Yes (yes)	Yes (NPS)	2.2 (V)	2.91	******
Hung et al. (2010)[89]	China	87 (87)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (no)	Yes (NPA, NPS)	4.7 (V)	0.90	******
Ip et al. (2016)[80]	China	17 (20)	7 (-)	0	Influenza A(H1N1)pdm09	Confirmed	No	Yes (no)	Yes (NPS, OPS)	5.0 (V)	0.21	******
Ito et al. (2012)[92]	Japan	34 (34)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	Yes (yes)	Yes (NPS)	5.5 (V)	0.35	*****
Killingley et al. (2010)[86]	United Kingdom	12 (21)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (yes)	Yes (NPS)	3.3 (V)	0.22	********
Launes et al. (2012)[85]	Spain	47 (47)	47 (47)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA)	3.0 (V)	0.48	*******
Lee et al. (2011)[87]	China	48 (48)	0	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA)	4.1 (V)	0.50	******
Lee et al. (2011)[95]	Singapore	578 (578)	231 (231)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPS)	4.1 (V)	5.96	*********
Li et al. (2010)[78]	China	581 (581)	522 (522)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (OPS)	6.7 (V)	5.99	******
Li et al. (2010)[93]	China	27 (59)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (non-treated group)	No (no)	Yes (NPA, NPS, OPS)	3.8 (V)	0.61	*******
Loeb et al. (2012)[76]	Canada	97 (218)	-	- (17)	Influenza A(H1N1)pdm09	Confirmed	No	No (no)	Yes (NPS)	4.9 (V)	2.25	*******

Study	Country											
Lu et al. (2012)[79]	China	13 (25)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir, zanamivir)	Yes (no)	Yes (NPS)	2.4 (V)	0.26	*******
Meschi et al. (2011)[82]	Italy	533 (533)	0	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPS)	4.8 (V)	5.50	*********
Ngaosuwankul et al. (2010)[100]	China	12 (33)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (yes)	Yes (NPA, NPS, OPS)	2.8 (V)	0.34	******
Rath et al. (2012)[81]	Germany	27 (41)	27 (41)	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (yes)	Yes (NPS)	4.1 (V)	0.42	*********
Suess et al. (2010)[77]	Germany	51 (129)	12 (-)	1 (1)	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	No (no)	Yes (NPA, NPS, OPS)	2.4 (V)	1.33	******
Thai et al. (2014)[91]	Vietnam	33 (123)	16 (-)	5 (28)	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (yes)	Yes (NPS)	5.8 (V)	1.27	*******
To et al. (2010)[90]	China	50 (50)	0	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir, nebulized zanamivir)	No (no)	Yes (NPA, NPS)	2.2 (V)	0.52	******
To et al. (2010)[97]	China	22 (22)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA, NPS, OPS)	2.5 (V)	0.23	*****
Watanabe et al. (2011)[102]	Japan	251 (251)	251 (251)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (yes)	Yes (NPA)	6.6 (V)	2.59	**********
Wu et al. (2012)[83]	China	64 (89)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	No (yes)	Yes (NPS)	2.3 (V)	0.92	******
Yang et al. (2011)[84]	China	251 (251)	-	0	Influenza A(H1N1)pdm09	Confirmed	N/A	No (yes)	Yes (OPS)	0.8 (V)	6.53	******

*References 13 and 35 are listed in the main body while those 42 and after are listed in Methods. Data shown as "-" were not obtained from the paper or authors.

†Responses of "no" for pharmacotherapy are based on no pharmacotherapy given to any patients or none reported in the study.

‡For studies reporting specimen measurements as individual sample data (either in numerical or graphical formats), the sample data was extracted for analysis.

§Specimen measurements were converted to rVLs based on the dilution factor for specimens immersed in transport media.

‖Abbreviations: viral meta-analysis (V), adult subgroup (A), pediatric subgroup (P), symptomatic/presymptomatic subgroup (S/Ps), asymptomatic subgroup (As).

¶The hybrid JBI Critical Appraisal Checklist was used, with more stars indicating lower risk of bias. Results from each study are shown in Supplementary Table 6.

#For these studies, only 2,147 (Lennon et al.) and 134 (Chen et al.) individual specimen measurements were obtained for the individual sample datasets.

☆For Chu et al., only specimen measurements at 20 DFSO were extracted, as 5-15 DFSO were equivalent specimens as those reported in Peiris et al.

Extended Data Table 2 | Descriptive parameters for subgroups of respiratory viral loads based on individual sample data

Category	n * (specimens)	n * (studies)	Weibull distribution parameters		Respiratory viral load, log₁₀ copies/ml				
			Scale factor (95% CI)	Shape factor (95% CI)	Mean (95% CI)[†]	SD[†]	90th percentile (95% CI)[‡]	95th percentile (95% CI)[‡]	99th percentile (95% CI)[‡]
SARS-CoV-2 (overall)[§]	3,778	24	7.01 (6.94-7.07)	3.47 (3.38-3.56)	6.28 (6.22-6.35)	2.04	8.91 (8.82-9.00)	9.61 (9.51-9.71)	10.88 (10.75-11.02)
SARS-CoV-1 (overall)[§]	303	5	6.34 (6.12-6.56)	3.37 (3.09-3.68)	5.69 (5.48-5.90)	1.86	8.11 (7.83-8.40)	8.77 (8.45-9.11)	9.96 (9.54-10.41)
A(H1N1)pdm09 (overall)[§]	512	10	7.39 (7.27-7.51)	5.43 (5.07-5.81)	6.81 (6.69-6.94)	1.45	8.62 (8.47-8.76)	9.04 (8.88-9.21)	9.79 (9.59-10.00)
SARS-CoV-2 (adult)[§]	3,532	18	6.99 (6.92-7.06)	3.47 (3.38-3.56)	6.27 (6.20-6.34)	2.04	8.89 (8.80-8.98)	9.59 (9.49-9.70)	10.86 (10.72-11.00)
SARS-CoV-2 (pediatric)[§]	185	7	7.47 (7.17-7.79)	3.65 (3.26-4.08)	6.73 (6.43-7.02)	2.06	9.39 (9.01-9.79)	10.09 (9.65-10.56)	11.36 (10.78-11.97)
SARS-CoV-2 (symptomatic/presymptomatic)[§]	1,503	20	7.39 (7.28-7.49)	3.79 (3.64-3.94)	6.66 (6.56-6.76)	2.01	9.21 (9.08-9.34)	9.87 (9.72-10.02)	11.06 (10.86-11.26)
SARS-CoV-2 (asymptomatic)[§]	2,212	6	6.72 (6.63-6.81)	3.32 (3.22-3.44)	6.01 (5.93-6.09)	2.02	8.64 (8.52-8.75)	9.35 (9.21-9.48)	10.64 (10.46-10.81)
SARS-CoV-2 (all DFSO)[§]	916	19	7.04 (6.90-7.18)	3.47 (3.30-3.65)	6.32 (6.19-6.45)	2.04	8.95 (8.78-9.13)	9.66 (9.45-9.86)	10.93 (10.66-11.21)
SARS-CoV-2 (-3 DFSO)[ǁ]	1	1	-	-	10.34	-	-	-	-
SARS-CoV-2 (-2 DFSO)[ǁ]	3	2	-	-	4.22 (2.41-6.02)	1.59	-	-	-
SARS-CoV-2 (-1 DFSO)	15	5	6.17 (5.11-7.47)	2.82 (1.89-4.19)	5.48 (4.25-6.70)	2.21	8.30 (6.88-10.02)	9.11 (7.44-11.16)	10.62 (8.38-13.45)
SARS-CoV-2 (0 DFSO)	48	10	6.63 (6.08-7.23)	3.46 (2.81-4.26)	5.97 (5.43-6.51)	1.85	8.43 (7.75-9.18)	9.10 (8.32-9.96)	10.31 (9.29-11.43)
SARS-CoV-2 (1 DFSO)	59	10	7.79 (7.23-8.40)	3.58 (2.91-4.40)	7.00 (6.42-7.59)	2.26	9.83 (9.12-10.61)	10.58 (9.75-11.49)	11.93 (10.84-13.14)
SARS-CoV-2 (2 DFSO)[¶]	69	13	7.42 (6.93-7.95)	3.61 (2.97-4.39)	6.67 (6.15-7.19)	2.17	9.35 (8.72-10.03)	10.06 (9.32-10.85)	11.33 (10.35-12.40)
SARS-CoV-2 (3 DFSO)[¶]	71	15	7.27 (6.74-7.84)	3.25 (2.69-3.93)	6.50 (5.96-7.04)	2.29	9.39 (8.71-10.14)	10.19 (9.38-11.06)	11.63 (10.54-12.82)
SARS-CoV-2 (4 DFSO)[¶]	81	15	6.84 (6.27-7.45)	2.66 (2.22-3.17)	6.08 (5.52-6.63)	2.51	9.36 (8.58-10.21)	10.34 (9.40-11.36)	12.15 (10.87-13.59)
SARS-CoV-2 (5 DFSO)[¶]	87	14	7.16 (6.67-7.68)	3.14 (2.65-3.72)	6.40 (5.91-6.89)	2.29	9.33 (8.69-10.02)	10.15 (9.40-10.96)	11.64 (10.63-12.74)
SARS-CoV-2 (6 DFSO)[¶]	102	14	6.81 (6.37-7.27)	3.09 (2.63-3.62)	6.07 (5.63-6.51)	2.24	8.92 (8.34-9.53)	9.71 (9.03-10.44)	11.16 (10.24-12.17)
SARS-CoV-2 (7 DFSO)[¶]	125	18	6.50 (6.13-6.89)	3.10 (2.69-3.58)	5.82 (5.45-6.19)	2.10	8.50 (8.01-9.03)	9.26 (8.67-9.88)	10.63 (9.84-11.49)
SARS-CoV-2 (8 DFSO)[¶]	119	18	6.49 (6.09-6.91)	2.99 (2.59-3.46)	5.79 (5.40-6.18)	2.14	8.57 (8.04-9.13)	9.35 (8.73-10.02)	10.80 (9.96-11.71)
SARS-CoV-2 (9 DFSO)[¶]	117	18	6.18 (5.76-6.63)	2.72 (2.35-3.15)	5.51 (5.11-5.91)	2.20	8.40 (7.82-9.01)	9.25 (8.57-9.98)	10.83 (9.90-11.85)
SARS-CoV-2 (10 DFSO)[¶]	110	16	5.76 (5.34-6.20)	2.61 (2.25-3.03)	5.13 (4.73-5.53)	2.11	7.92 (7.34-8.55)	8.76 (8.07-9.51)	10.33 (9.38-11.37)

*These two columns summarize the cumulative number of specimens (left) collected from the number of studies (right) for each category in the systematic dataset.

[†]The mean and sample SD were calculated on the entire set of individual sample data for each category.

[‡]The Weibull quantile distributions were used to determine rVLs at the 90th, 95th and 99th cps.

[§]These categories included only rVL data from positive (above the detection limit) qRT-PCR measurements.

[ǁ]Data for earlier DFSO were excluded from distribution fitting based on limited data, and empty cells were marked with "-".

[¶]These categories included negative qRT-PCR measurements (set at the detection limit to estimate rVLs; n = 3, 3, 6, 8, 12, 15, 13, 17 and 14 specimens for 2-10 DFSO, respectively) for cases that tested positive at an earlier DFSO.

1056 **Extended Data Table 3 | Model parameters describing SARS-CoV-2 kinetics in the respiratory tract**

Parameter	Description	Value (95% CI)	Units
β	Infection rate constant	4.02 (3.01-5.03)	$\times 10^{-7}$ (copies/ml)$^{-1}$ day^{-1}
p	Cellular shedding rate of virus	1.11 (0.51-1.71)	copies/ml day^{-1} cell^{-1}
c	Clearance rate of virus	3.82 (0.17-7.47)	day^{-1}
δ	Clearance rate of infected epithelial cells	0.55 (0.23-0.87)	day^{-1}
$R_{0,c}$	Cellular basic reproductive number	10.6	unitless
V_0*	Initial rVL parameter	4	copies/ml
I_0*	Initial number of infected cells	0	cells
T_0*	Initial number of uninfected cells	5×10^7	cells

1057 *Initial values were used as inputs for the numerical estimation of the model parameters.